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Abstract Crohn’s disease is a disorder of unknown eti-
ology and complicated pathogenesis. A substantial amount
of evidence has accumulated recently and has been applied
to clinical practice. The present guidelines were developed
based on recent evidence and the formal consensus of
experts relevant to this disease. Here we provide an over-
view of these guidelines, as follows.
• Target disease: Crohn’s disease
• Users: Clinical practitioners in internal medicine,
surgery, gastroenterology, and general practice
• Purpose: To provide appropriate clinical indicators to
practitioners
• Scope of clinical indicators: Concept of Crohn’s
disease, epidemiology, classifications, diagnosis, treat-
ment, follow up, and special situations
• Intervention: Diagnosis (interview, physical examina-
tion, clinical laboratory tests, imaging, and pathology)
and treatment (lifestyle guidance, drug therapy, nutri-
tional therapy, surgery, etc.)
• Outcome assessment: Attenuation of symptoms, induction
and maintenance of remission, imaging findings, quality of
life (QOL), prevention of complications and harm of therapy
• Methods for developing these guidelines: Described in
the text
• Basis of recommendations: Integration of evidence
level and consensus of experts
• Cost-benefit analysis: Not implemented
• Evaluation of effectiveness: Yet to be confirmed
• Status of guidelines: Updated version of the first
Guidelines published in 2010
• Publication sources: Printed publication available and
electronic information in preparation
• Patient information: Not available
• Date of publication: October 2011
These guidelines were intended primarily to be used by
practitioners in Japan, and the goal of these guidelines is to
improve the outcomes of patients with Crohn’s disease.
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Introduction
Crohn’s disease (CD) is a complicated disorder of unknown
etiology and pathogenesis, involving mainly the small
intestine and the colon, but possibly the entire gastrointes-
tinal tract, as well as other organs. Owing to the substantial
amount of newer knowledge relevant to the care of CD, the
diagnostic and therapeutic strategies for CD have signifi-
cantly changed, and guidelines to provide appropriate clin-
ical indicators have become necessary. The Japanese Society
of Gastroenterology, in collaboration with the Research
Group of Intractable Inflammatory Bowel Disease subsi-
dized by the Ministry of Health, Labour and Welfare of
Japan, established committees to develop clinical guidelines
for CD. The first edition of the guidelines was published in
2010, and an updated version with minor modifications,
adding newer therapeutic modalities, was published in 2011.
This English version was produced and edited based on the
existing updated guidelines.
1. Purpose and focus
The purpose of developing these guidelines was to
provide appropriate clinical indicators for CD to contribute
to improved outcomes for patients with CD. The statements
in these guidelines cover the standard concept of this dis-
ease, as well as describing interventions for diagnosis,
treatment, and follow up. The guidelines include descrip-
tions of and interventions for gastrointestinal lesions,
complications, extra-intestinal complications, and special
situations in adults with CD. Special considerations for
children or elderly patients are not included.
2. Users and settings
The target users of these guidelines are practitioners who
provide care for CD patients in clinical settings. The guide-
lines are intended not only for the use of gastroenterologists,
but also for the use of internists, surgeons, and general prac-
titioners who may have the opportunity to care for patients
with CD. Although the present guidelines are not intended for
the use of patients, patient information may be developed from
the guidelines with minor modifications, as clinical questions
are extracted from the patient’s point of view.
3. Features
The clinical questions (CQs) have been extracted from
the patient’s point of view. The basic process was carried
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out according to the international standardization of
guideline development, with particular emphasis on the
existing clinical evidence. When evidence was insufficient
or inappropriate for practice in Japan, expert opinions were
incorporated. In other words, these guidelines aim to pro-
vide clinical indicators, with scientific validity as well as
applicability and flexibility. The guidelines were developed
by the collaborative efforts of the Japanese Society of
Gastroenterology and the Research group of Intractable
Bowel Disease subsidized by the Ministry of the Health,
Labour and Welfare of Japan.
The major differences from the corresponding existing
clinical practice guidelines formulated by the Research
Group of the Ministry of Health, Labour and Welfare of
Japan are: (1) the present guidelines place emphasis not
only on the healthcare provider’s point of view but also on
the patient’s; (2) the statements are based on literature
evidence with review by an expert group; (3) each indicator
is accompanied by a strength of recommendation, defined
according to the level of relevant evidence and the expert
consensus; (4) not only specialists but all practitioners were
intended as potential users, and (5) the scope and limita-
tions of these guidelines are explicitly presented.
4. Methods for developing the guidelines
Independent Committees for developing clinical indi-
cators (Development Committee) and for assessment
(Assessment Committee), each of which consisted of
experts in gastroenterology, general internal medicine,
surgery, and clinical epidemiology, were established
according to the methods provided by the Guideline
Supervision Committee of the Japanese Society of Gas-
troenterology. The basic process of development was car-
ried out by repeated correspondence between these two
committees by which they prepared, evaluated, and modi-
fied statements, eventually creating the most appropriate
statements for the guidelines.
The Development Committee extracted CQs in the
clinical practice field from the patient’s point of view, and
an external media center collected literature published up
to 2007 relevant to these CQs, mainly through MEDLINE,
the Cochrane Library, and the Japan Medical Abstracts
Society. In addition, the members of the Development
Committee manually added important literature published
up to 2008 to the references in their respective areas.
The members of the Development Committee examined
the levels of evidence (Table 1) for the literature items.
Literature items with an evidence level of III or higher
were adopted initially, but those with lower levels of evi-
dence were also adopted if relevant to clinical practice.
Original articles, as well as reviews and existing guide-
lines, were selected, with consideration given to clinical
interventions that improved patient outcomes, irrespective
of the health insurance coverage in Japan. For multiple
articles with different levels of evidence, the higher level
was adopted. Randomized controlled trials with unwar-
ranted quality were regarded as level III. If a statement was
based on an unclear citation, it was considered to be the
author’s opinion and was regarded as level VI.
Statements of recommendation and the corresponding
comments were created on the basis of the selected liter-
ature, or, for issues without existing evidence, the state-
ments of recommendation and the corresponding
comments were created based on the opinions of the
members of the Development Committee. The original
statements and comments were evaluated by the Assess-
ment Committee, and repetitive modifications were made
by the collaborative work of both committees. The
Assessment Committee and three external members eval-
uated the appropriateness of the statements of recommen-
dation on a 1- to 9 scale (from 1 equaling ‘‘most
inappropriate’’ to 9 equaling ‘‘most appropriate’’) accord-
ing to the Delphi method. The final results after three
Delphi rounds were reflected in the adoption of the state-
ments of recommendation and the determination of the
grades of recommendation.
As there are some therapeutic modalities that were
approved for clinical use after the publication of the Jap-
anese Society of Gastroenterology’s Clinical Practice
Guidelines for Crohn’s Disease (published by Nankodo
Co., Ltd., Tokyo, Japan), additional searches of the litera-
ture relevant to these therapies were performed, and the
same process as that described above was employed to
create statements of recommendation for these therapies.
5. Criteria for setting recommendation grades and
interpretations
The grade of a recommendation is usually determined
parallel to the quality of the evidence on which the state-
ment of recommendation is based, but there are some
difficult issues with this process. The level of evidence
Table 1 Evidence levels of literature-based information
I Systematic review/Meta-analysis of randomized controlled
trials
II Based on one or more randomized controlled trials
III Based on a non-randomized controlled trial
IVa Analytical epidemiological study (cohort study)
IVb Analytical epidemiological study (case–control study or cross-
sectional study)
V Descriptive study (case report or case series)
VI Opinion of an expert committee, or an expert, not based on
patient data
J Gastroenterol (2013) 48:31–72 33
123
does not assure the quality of the results of clinical studies,
but is defined by the study design. There are some time-
honored clinical practices without high evidence; on the
other hand, there are some novel modalities in the recent
literature with a high level of evidence but whose clinical
usefulness is yet to be determined. In addition, a clinical
intervention directly affecting human life is not a subject
for a randomized controlled trial. For these issues, an
expert opinion is essential.
We were concerned about the possibility of biased
consensus formation owing to the opinions of the domi-
nating expert in the group and the lack of clarity of the
impact of the consensus on the recommendations. In these
guidelines, the Delphi method was used to form a sound
consensus. In addition, the relationship of the consensus to
the recommendation grade was clearly defined (Table 2).
As a rule, the recommendation grades presented in these
guidelines were determined following the above-mentioned
principles; however, some statements of recommendation
that were considered to be obvious by the consensus of the
experts even without good evidence were graded as B
rather than C1: they are indicated as B*. The meanings of
the grades thus determined are described in Table 3. Note
that the clinical indicators that were evaluated by the
consensus of the experts as not being appropriate (a Delphi
median value of 6 or less) were not recommended, as a rule
(i.e., those graded as C2 or D), regardless of the quality of
the related literature-based evidence.
6. Internal review of the guidelines
The final drafts of the Clinical Practice Guidelines for
Crohn’s Disease (published by Nankodo Co., Ltd., Tokyo,
Japan) were put up on the website of the Japanese Society
of Gastroenterology for 2 months to invite opinions from
the members of the Society. They were also distributed to a
total of 68 research group members and collaborators of the
Research Group of Intractable Inflammatory Bowel Dis-
ease subsidized by the Ministry of Health, Labour and
Welfare of Japan (who represent experts on inflammatory
bowel disease in Japan) for their evaluation of the validity
of the guidelines. Minor modifications, made by the
adoption of some comments, were made by the collabo-
ration of the Assessment and Development Committees.
7. Applicability of the guidelines
The literature articles that were used as the basis for
creating the statements of recommendation were selected
considering their feasibility in clinical practice in Japan.
Accordingly, theclinical indicators in these guidelines can
be applied to daily clinical practice without any change of
current systems/organizations, and therefore they probably
do not require any notable additional medical resources.
Examining whether these clinical indicators would be
covered by the Japanese health insurance system, it
appeared that the great majority of them would fall within
the coverage of the insurance system. The exceptional
indicators that fall outside the range of insurance coverage
are accompanied by a note.
8. Benefits and risks of applying the guidelines
The statements of recommendation in these guidelines
are standard clinical indicators for CD. They support the
decision-making of practitioners, but they neither regulate
nor restrict their clinical practice. They are not intended to
be a basis for legal judgments. With the support of spe-
cialists as needed, and with the flexible use of the guide-
lines giving sufficient consideration to the patients’ values,
we believe the guidelines will contribute to the improved
quality of clinical practice and patient outcomes.
In actual clinical practice, the patients’ values and
practitioners’ sound judgment are paramount, and it would
be inappropriate for these guidelines to be used to control
clinical practice, to provide a legal basis for clinical prac-
tice, or to restrain practitioners’ discretion, and these
guidelines would, rather, be considered harmful if used in
such manner.
Table 2 Criteria for setting recommendation grades
Level of evidence Consensus (median value of Delphi evaluation)
8 or more 7 6–4 3 or less
I A A C2 D
II A B C2 D
III B B C2 D
IV B C1 C2 D
V C1 (B*) C1 C2 D
VI C1 (B*) C1 C2 D
Table 3 Interpretations of recommendation grades
A Strong recommendation, with high level of evidence
B Moderate recommendation, with certain level of evidence
Supported by an intermediate level of evidence and considered
to be clinically useful
Supported by a high level of evidence but not considered to be
clinically very useful
Evidence level is low, but usefulness has already been
established in clinical practice
C1 Recommendation to be done, without a high level of evidence
C2 Recommendation not to be done, without a high level of
evidence
D Recommendation not to be done, as evidence indicates
ineffectiveness or harm
34 J Gastroenterol (2013) 48:31–72
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9. Independence of the guidelines
These guidelines were developed for common objec-
tives by members of the Japanese Society of Gastroenter-
ology and by the Research Group of Intractable
Inflammatory Bowel Disease subsidized by the Ministry of
Health, Labour and Welfare of Japan. The guidelines were
developed independent of any other funding sources and
without the cooperation or coordination of any other aca-
demic organization, healthcare-providing organization, or
patient organization.
A comprehensive list of potential conflicts of interest
between health/medical industries and members of the
various committees and institutions/organizations who
developed the guidelines is provided (see Table 4). Such
relationships are related to the individual members or the
institutions, and no funding has been provided for the
development of these guidelines.
10. Future issues
For these guidelines, the statements of recommenda-
tion were created with an emphasis on literature-based
evidence in response to the CQs raised from the patients’
point of view, and the statements were reviewed and
modified by a group of experts. The recommendation
grades were determined on the basis of the levels of
evidence and then clearly integrated by formal consensus.
As a result, we believe that these guidelines would pos-
sess internal validity, and clinical applicability and flex-
ibility. They have not, however, been evaluated for their
effectiveness, in terms of actual contribution to the
improved quality of clinical practice for CD, and this is an
issue to be addressed later.
With the accumulation of newer evidence, a process of
revision of the guidelines will be necessary. These
guidelines may need to be revised and supplemented by
3 years or so after their publication. Assessment by the
users should be considered for revision, and therefore
constructive criticisms are invited.
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How to read the guidelines
In the text, CQs are presented according to clinical cate-
gories, and each CQ is followed by one or more corre-
sponding statements of recommendation. Each of the
statements is accompanied by a recommendation grade that
indicates the strength of the recommendation. The recom-
mendation grade, which is defined in Table 3, is followed
by the levels of evidence of the literature articles that are
the basis for the recommendation (in Japan and overseas)
and the value of the expert group consensus (i.e., the
Delphi evaluation median value). The comments provide a
general description of the clinical practice related to each
CQ. The lists of references are presented after the text.
Clinical questions (CQs) and statements
I. Disease concept
I-1. Definition
CQ1: What is CD? [2]
• CD is a chronic disease of unknown causes that mainly
presents as granulomatous inflammatory lesions of the
gastrointestinal tract. C1 (Japan VI, overseas VI; 8).
Comments
CD is a chronic inflammatory disease of the gastrointestinal
tract characterized by discretely distributed transmural granu-
lomatous inflammations and fistulas. Lesions of CD may occur
throughout the entire gastrointestinal tract, but they occur most
commonly in the small intestine, the colon (especially the ile-
ocecal region), and the perianal region [2]. The disease occurs
at a young age, and lasts chronically, with remissions and
relapses of symptoms and signs such as abdominal pain, diar-
rhea, hematochezia, fever, perianal symptoms, and weight loss,
resulting in a reduced quality of life for the patients. Also, CD
may cause extra-intestinal complications in the joints, the skin,
the eyes, and other parts of the body. CD and ulcerative colitis
(UC) are together referred to generically as inflammatory
bowel disease (IBD). Although they have common and/or
similar features, they are considered to be mutually distinct.
I-2. Epidemiology
CQ2: How common is CD, in what age group does it
occur, and in Japan, are there any differences
from other countries? [2–7]
• The number of CD patients in Japan is steadily
increasing, with a current estimate of more than 30,000.
CD is more prevalent among men than women, at an
approximate ratio of 1.8: 1.0. B* (Japan V; 9).
• CD occurs at comparatively young ages, more com-
monly from the late teens to the early 30s. B* (Japan
V; 9)
• The prevalence and incidence of CD in Europe and
North America are higher than those in Japan, and
female preponderance in those areas is noted. C1
(overseas V; 8).
Comments
A Japanese nationwide epidemiological survey in 1991
reported that the prevalence of CD was 5.85 per
100,000 (7.94 among men and 3.83 among women) and
that the incidence of CD was 0.51 per 100,000 (0.71
among men and 0.32 among women) [3]. The figures
were clearly lower than those in Europe and North
America. Although no such survey has been conducted
since then, the estimated number of CD patients has
steadily increased in Japan [4], and more than 30,000
patients received registered medical services for CD in
2009.
The onset of CD is usually in young people, commonly
in the early third decade among men and in the late second
decade among women [2–4]. According to the Japanese
national registration record for medical services, it is esti-
mated that CD occurs more commonly in the third and
early fourth decades among men and in the late second
decade among women [5].
The incidence in countries overseas is usually higher
than that in Japan, although it varies from region to region;
there are a substantial number of regions with a CD inci-
dence rate of around 10 per 100,000 in Europe and North
America. It has been shown that the prevalence of this
disease has been increasing globally from year to year [6].
In general, CD is more common in women in Europe and
North America, unlike in Japan [7]. At present, Japan is
ranked in the middle for the prevalence and incidence rates
of CD, together with South Korea, Oceanic countries, and
South Africa [4].
I-3. Etiology
CQ3: What causes CD? Is it inherited? What are
the risk factors? [8–19]
• The causes of CD have not been identified. C1 (Japan
VI, overseas VI; 8).
• A tendency for familial occurrence is noted. B (over-
seas IVa; 8).
36 J Gastroenterol (2013) 48:31–72
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• Some causal relationships between diet and CD have
been reported, though the evidence is not conclusive. B
(Japan IVb, overseas IVb; 8).
• Smoking is a risk factor for CD. B (overseas III; 8).
• Nonsteroidal anti-inflammatory drugs (NSAIDs) and
oral contraceptives are potential factors for the exac-
erbation of CD. C1 (overseas IVb; 7).
Comments
The causes of CD have not yet been identified. The current
international consensus is that the intestinal inflammation
is caused by a disordered immunomodulatory mechanism,
with exposure to various environmental factors in an
individual with genetic susceptibility [8–10]. A somewhat
higher incidence of CD is reported among relatives [11,
12], and reports of familial clustering indicate the presence
of a genetic mechanism. Studies are underway to find the
disease susceptibility genes for CD.
Regional differences in the incidence of CD suggest a
causal relationship between diet and CD, and many clinical
and epidemiological studies have been reported. Some
overseas reports found a causal relationship between CD
and high intakes of carbohydrates (particularly sugar) [13,
14], and some reports from Japan showed a causal rela-
tionship between CD and ‘‘fast foods’’ with high contents
of fats and sugar [15]. However, no food has been con-
cluded to be a risk factor for CD.
Smoking is considered to be a risk factor for CD. Reports
have shown that smoking is not only related to the onset,
relapse, and exacerbation of CD, but also that smoking ces-
sation lowered the postoperative recurrence rate [16]. Smok-
ing also affects the efficacy of infliximab treatment [17].
Among many drugs evaluated, NSAIDs and oral con-
traceptives have been shown to be associated with the onset
and exacerbation of CD [18, 19].
I-4. Pathophysiology, classification, and disease activity
CQ4: What kind of pathophysiological conditions are
present in CD, and how are they recognized? [20]
• To provide appropriate treatment, it is necessary to
exactly recognize the disease extent, disease pattern,
and degree of disease activity. B* (Japan VI, overseas:
VI 9).
Comments
The pathophysiological conditions of CD are complex, but
correct recognition is the first step for appropriate
management. It is important to identify the distribution of
the lesions, to recognize the disease pattern, and to assess
disease activity/severity.
The lesions are often found in the small intestine, the
colon (particularly in the ileocecal region), and the perianal
region, and are classified as the ileal, colonic, and ileo-
colonic types. Note, however, that lesions can occur at any
site in the gastrointestinal tract; moreover, CD may have
extra-intestinal complications causing systemic involve-
ment. Treatment plans differ according to the sites of
involvement.
According to an international proposal, the disease
patterns can be classified as ‘‘Inflammatory’’, ‘‘Penetrat-
ing’’, and ‘‘Stricturing’’ [20]. Recognition of the disease
pattern is also important for appropriate treatment.
Furthermore, it is necessary to assess the disease activity.
Treatment during the remission phase when the symptoms
have abated or are absent is different from treatment during
the active phase when various symptoms interfere with
daily life. For the objective evaluation of the disease
activity and severity, the Crohn’s Disease Activity Index
(CDAI) is available, but it is not suitable for daily clinical
practice. The Index of Inflammatory Bowel Disease (IO-
IBD) is simple, but it does not assist in the selection of
appropriate treatment options. At present, there is no uni-
versal classification of CD severity available for use in
Japan. In general clinical practice, the disease activity can
be assessed by the comprehensive evaluation of subjective
symptoms, clinical findings, and laboratory investigations.
I-5. CD progression
CQ5: How does CD progress in the long term? Is there
an increased risk of cancer? Is life expectancy
shortened? [21–29]
• CD persists, with remissions and relapses, for a long
period of time. C1 (Japan VI, overseas VI; 9).
• During disease progression, the daily life of CD
patients is often disturbed. C1 (Japan V, overseas V; 8).
• The incidence of cancer among CD patients is slightly
elevated. B (Japan V, overseas IVb; 8).
• The life expectancy of CD patients is slightly shorter
than that of healthy individuals. C1 (Japan V, overseas
IVb; 7).
Comments
CD is a disease that persists for a long period of time, with
repeated active phases and remission phases. The symp-
toms and complications in the active phase make it difficult
for patients to live a normal daily life. In countries
J Gastroenterol (2013) 48:31–72 37
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overseas, 15 % of CD patients become unable to work
5–10 years after the diagnosis [21]. According to a cross-
sectional study in Japan, fewer than 30 % of CD patients
are able to work in full-time employment throughout the
year [22]. Intra- and extra-intestinal complications are
considered to have the most negative impact on the
activities of daily living (ADL) among CD patients [23].
An overseas meta-analysis report indicates that the
relative risks of cancer in the colon and the small intestine
in CD patients are 2.4 and 28.4, respectively [24].
Although the relative risk of small-intestinal cancer is
conspicuously higher than that of the colon, its signifi-
cance is not clear because the absolute number of these
cancer cases is very small. According to a Japanese report
on the association of CD and cancer in the colon, the small
intestine, and the anal canal, most cases of such cancers
are discovered at an advanced stage. Most reports on the
incidence of cancer in CD patients in Japan are based on
case-series studies, but some controlled studies suggest
that the incidence in Japan is similar to that in Europe and
North America [25, 26].
Six of seven overseas area cohort studies estimate that
the mortality in CD patients has been greater than 1.0, and
has been stable in the past 40 years [27]. Two reports from
Japan showed different conclusions: one reported that
mortality among CD patients was higher, while the other
reported that mortality was similar to that of the healthy
population [28, 29]. In general, CD does not seem to sig-
nificantly reduce the life expectancy of the patients.
II. Diagnosis (Fig. 1)
II-1. Clinical symptoms
CQ1: What are the clinical symptoms of CD? [30]
• Abdominal pain and diarrhea are the most common
symptoms. Symptoms due to perianal lesions and
hematochezia are also commonly encountered. C1
(Japan VI, overseas V; 8).
• Although systemic symptoms and signs such as weight
loss, fever, general malaise and anorexia, and oral
aphthous ulcerations are often observed, they are not
highly specific for CD. C1 (Japan VI, overseas V; 8).
Comments
Abdominal pain (70 %) and diarrhea (80 %) are commonly
encountered at the time of diagnosis. Hematochezia is
observed in 30 % of patients, but is usually not massive.
Generally, abdominal pain is more common in the small-
intestinal type, whereas hematochezia and diarrhea are
more common in the colonic type. In the course of the
disease progress, perianal lesions are observed in more than
50 % of patients, and fistulas and abscesses manifest in
approximately 15 % of patients [30].
Systemic symptoms and signs such as weight loss and fever
are found in 40–70 % of patients at the time of diagnosis.
Weight loss is more common in the small-intestinal type.
Systemic symptoms such as general malaise and anorexia,
aphthous stomatitis, and shallow ulcers in the oral cavity are
often observed during the progress of the disease, but they are
not highly specific for CD [30]. Extra-intestinal complications
such as lesions in the joints, skin, and eyes are observed in
approximately 2–10 % of patients [30].
CQ2: What are the complications associated with CD?
[30–35]
• Intestinal complications of CD include stenosis, fistulas
(internal and external), abscess formation, massive
hemorrhage, and colorectal cancer. B* (Japan V,
overseas V; 9).
• Extra-intestinal complications of CD include joint
lesions (e.g., joint pain, acute peripheral arthritis, and
reactive arthritis), skin lesions (e.g., erythema nodosum,
Sweet’s disease, and pyoderma gangrenosum), eye lesions
(e.g., iritis and episcleritis), and primary sclerosing
cholangitis (PSC). C1 (Japan V, overseas V; 8).
• Complications to which children are susceptible
include growth retardation, osteoporosis, and angitis.
C1 (Japan V, overseas V; 7).
Comments
Intestinal complications of CD include stenosis, internal and/or
external fistulas, and abscess formation, any of which are not
infrequently candidates for surgical interventions. Complica-
tions increase with the disease progress [31]. CD with intestinal
complications is known as the disabling type [31], and thus it is
important to prevent these complications or treat them appro-
priately in order to maintain the patients’ QOL. Massive
hemorrhage occurs in 0.6–5 % of patients, and it usually arises
from anastomotic sites and the small intestine [30].
Signs of joint lesions include joint pain or acute
peripheral arthritis (type 1: fewer than five joints, mainly in
the large joints, associated with the CD activity) and
reactive arthritis (type 2: polyarthritis in the small joints,
not associated with the CD activity) [32]. Joint symptoms
are found in 30 % or more (arthralgia, 14.3 %; type 1
arthritis, 6 %; type 2 arthritis, 4 %; and axial arthropathy,
9.9 %) [32]. The reported association of CD with skin
lesions, including erythema nodosum, Sweet’s disease, and
pyoderma gangrenosum, has been increasing. According to
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an overseas report, approximately 2.2 % of IBD patients have
skin symptoms [33, 34]. The frequency of erythema nodosum
is about three times as high as that of pyoderma in IBD
patients. Both skin conditions are more likely to manifest as a
complication of CD rather than UC. Sweet’s disease is rarely
found in CD patients (30 reported cases in Europe and North
America) [35]. Nonspecific skin eruptions are more often seen
among CD patients than in healthy people, but they are not
correlated with the disease activity.
Iritis and episcleritis are found in 1–2 % of IBD patients
[34]. PSC as a complication of CD is found at a rate of
1–3 %, which is lower than that in UC. Psoriasis is more
common in CD patients and their siblings than in the
general population.
Complications more often found in children include
growth retardation, osteoporosis, and angitis [30]. The
frequency of extra-intestinal complications is higher
among children with IBD than in adults with IBD, and
some reports indicate that the rate of such complications in
children is as high as 35 % [30, 32, 34].
CQ3: What kind of perianal lesions are caused by CD?
[36–38]
• Perianal lesions include anal fissures, anal ulcers, skin
tags, anal fistulas, perianal abscesses, anovaginal fis-
tulas, cavitating ulcers, piles, and anal canal cancer. C1
(Japan V, overseas V; 8).
Preferential age of onset:
Late teens to early third decade 
Principal symptoms:
Chronic abdominal pain and diarrhea
Physical findings: 
Systemic symptoms:  
 weight loss, fever, and general malaise 
Anal lesions:  
 anal fissures, perianal ulcers, skin tags 
Others:  
 features similar to appendicitis, bowel 
obstruction
Laboratory test: 
Inflammatory markers: white blood cell count, CRP, platelet count, and 
erythrocyte sedimentation rate 
Malnutrition: low serum total protein, serum albumin, and cholesterol 
Other: anemia 
Diagnostic imaging: 
Radiography (barium enema, small 
intestine, upper gastrointestinal tract): 
cobblestone-like appearance, 
longitudinal ulcers, irregular-shaped 
ulcers 
Endoscopy (lower and upper 
gastrointestinal tract): aphthous 
ulceration and bamboo joint-like 
appearance (stomach) 
Biopsy (lower and upper gastrointestinal 
tract): noncaseating epithelioid cell 
granuloma
Differential diagnosis:  
- Ulcerative colitis 
- Ischemic colitis 





Extent of lesions:  
Ileal type, colonic type, and 
ileocolonic type 
Disease pattern:  
Inflammation, fistulation, and 
stenosis 
Complications:  
Intestinal and extra-intestinal 
complications 
Fig. 1 Diagnostic approach in
Crohn’s disease. CRP
C-reactive protein
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Comments
Perianal lesions are found in more than 50 % of patients
with CD, and often precede other symptoms (36–81 %).
The frequency of perianal lesions as complications is sig-
nificantly higher in cases of CD with rectal stenosis than in
those without such stenosis [36–38].
Hughes [37] classified perianal lesions according to the
pathological conditions, as follows: primary lesions, i.e., deep
ulcers (deep anal fissures and anal ulcers) caused by CD itself;
secondary lesions, i.e., secondary lesions originating from the
primary lesions via infection or other causes; and incidental
lesions, i.e., lesions not related to CD. Recently, cases of anal
canal cancer as a complication have also been reported in
Japan. It is necessary to survey these lesions carefully in
patients with long-term progression of the disease.
II-2. Medical interview and physical examination
CQ4: What kind of symptoms and physical findings
make CD suspected? [39]
• Chronic abdominal pain and/or diarrhea in young individuals
suggest the possibility of CD, especially when accompanied
by weight loss and fever. C1 (Japan VI, overseas VI; 8).
• On physical examination, characteristic perianal lesions
(preferably checked by colorectal surgeons familiar with
CD), findings similar to appendicitis, bowel obstruction, and
rectal bleeding indicate CD. C1 (Japan VI, overseas VI; 7).
• Although the onset of CD is usually at young ages, it is
not rare in the elderly. C1 (Japan VI, overseas VI; 7).
Comments
According to the Proposed Diagnostic Criteria for Crohn’s
Disease [39], this disease presents with initial symptoms of
‘‘abdominal pain, diarrhea, weight loss, fever, perianal
lesions, symptoms particularly similar to appendicitis, bowel
obstruction, intestinal perforation, and/or massive hemor-
rhage. Furthermore, it may occur with perianal lesions and/or
fever (of unknown causes), without abdominal symptoms’’.
II-3. Diagnostic strategies
CQ5: If CD is suspected, how do physicians proceed
to the diagnosis? What kind of investigations are
required? [40, 41]
• Obtain blood tests to check for inflammatory activity,
malnutrition, and iron-deficiency anemia. C1 (Japan VI,
overseas VI; 8).
• Use imaging procedures to check for morphological
findings characteristic of CD. C1 (Japan VI, overseas
VI; 8).
• Exclude infectious enterocolitis (including tuberculo-
sis), if necessary, by stool culture and other tests. C1
(Japan VI, overseas VI; 8).
• Apply tests to check for intestinal complications
according to the symptoms. C1 (Japan VI, overseas
VI; 8).
Comments
Apply blood tests to examine for abnormal inflammatory
responses (in terms of white blood cell count, C-reactive
protein [CRP], platelet count, and erythrocyte sedimenta-
tion rate [ESR]), malnutrition (low serum total protein and
albumin, and/or low total cholesterol), and anemia.
Employ lower gastrointestinal endoscopy (including
histological evaluation), barium enema, and/or small-
intestinal contrast radiography as imaging examinations.
Check for longitudinal ulcers, a cobblestone-like appear-
ance, stenosis, and fistulas, which are characteristic of CD
in such examinations. Use upper gastrointestinal endos-
copy with biopsy as much as possible to detect multiple
aphthous ulcerations, ulcers, stenosis, and a cobblestone-
like appearance as lesions of CD in the upper gastroin-
testinal tract [40, 41]. Imaging procedures are usually
used to exclude similar disorders. Stool cultures and
serum antibodies are utilized to check for infectious
enterocolitis.
Regarding intestinal complications, use computed
tomography (CT) and/or magnetic resonance imaging
(MRI) to check for the presence and the severity of perianal
abscesses, anal fistulas, and intra-abdominal abscesses.
CQ6: What morphological examinations are necessary
to make a diagnosis of CD? [40, 41]
• Lower-gastrointestinal endoscopy, barium enema radi-
ography, small-intestinal radiography, upper-gastroin-
testinal endoscopy, upper-gastrointestinal contrast
radiography, and histopathological examination are
necessary. B* (Japan VI, overseas VI; 9).
Comments
The common sites of involvement by CD are the colon and
the distal ileum; therefore, barium enema radiography,
lower-gastrointestinal endoscopy (including examination
of the terminal ileum and histological evaluation of biopsy
specimens), and small-intestinal radiography are usually
conducted prior to other examinations.
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Although upper-gastrointestinal endoscopy is not indis-
pensable, it should be used in cases where a definitive
diagnosis could not be made by barium enema radiography
or lower-gastrointestinal endoscopy.
Small-intestinal endoscopy is helpful in cases where CD
lesions are not found on the lower and upper gastrointes-
tinal endoscopic examinations or on contrast radiography
despite the clinical suspicion of CD. Although capsule
endoscopy is used overseas to detect lesions in the small
intestine, it has not been approved for clinical use in Japan
because of potential complications at the site of a stenosis.
CQ7: What kind of laboratory markers are useful
to evaluate the activity of CD? [42–44]
• Markers of inflammatory response (CRP and ESR) are
considered to correlate with the disease activity. C1
(Japan VI, overseas VI; 8).
• Nutritional indices (serum total protein and serum
albumin) also reflect the disease activity in many cases.
C1 (Japan VI, overseas VI; 7).
• There is no single index with which to quantitate
disease activity to enable an objective assessment;
therefore, it is necessary to assess CD disease activity
in a comprehensive manner. C1 (Japan VI, overseas
VI; 9).
Comments
The disease activity of CD is generally assessed by the
CDAI or IOIBD. The CDAI is the most commonly used
assessment tool worldwide [42]. CD causes lesions at any
site along the entire gastrointestinal tract, and the sites and
extent of lesions are related to the disease activity. Gen-
erally, the markers of inflammatory response (CRP and
ESR) are comparatively well correlated with the CDAI
scores indicating the disease activity, but with occasional
discrepancies. In patients with severe and extensive dis-
ease, especially those with extensive small-intestinal
lesions, hypoproteinemia is often present. However, values
for nutritional indices may be affected by treatments such
as nutritional therapy. Accordingly, no single laboratory
test can contribute to the assessment of the disease activity.
The Endoscopic Index of Severity of Crohn’s Disease
(CDEIS) has been proposed as an endoscopic index of
disease activity [43, 44]. This index is obtained by dividing
the intestinal tract into five segments (the rectum, the sig-
moid/descending colon, the transverse colon, the ascending
colon/cecum, and the ileum), determining scores and
obtaining subtotals according to the depth and length of
ulceration and the area of lesions in each segment, and then
calculating an average based on the number of segments
with lesions, and adding points for stenosis to the average.
Calculation of values in this index is complicated and time-
consuming. The index is not commonly used to evaluate
disease activity in clinical practice.
II-4. Endoscopy
CQ8: When is endoscopic examination necessary
to make a diagnosis of CD? [39, 40, 43–46]
• When clinical symptoms and the laboratory test results
suggest CD, promptly examine the patient using lower-
gastrointestinal endoscopy (including an observation of
the terminal ileum) and histological evaluation of
biopsy specimens. C1 (Japan VI, overseas VI; 8).
• Examine the patient using upper-gastrointestinal endos-
copy when a definitive diagnosis has not been made
with lower-gastrointestinal endoscopy or when the
patient complains of symptoms in the upper gastroin-
testinal tract. C1 (Japan VI, overseas VI; 8).
Comments
CD can affect the entire gastrointestinal tract, but the
common sites are the colon and the distal ileum. When
clinical symptoms and the laboratory test results suggest
CD, promptly examine the patient using lower-gastroin-
testinal endoscopy, including an observation of the termi-
nal ileum, to make a definitive diagnosis, to determine the
extent and severity of inflammation, and also to take a
biopsy sample for histological examination [40, 43–46].
Endoscopy has recently been employed for the treatment of
stenosis. Small-intestinal balloon endoscopy may be useful.
Upper-gastrointestinal lesions are not rare and may
occur at a high rate (17–75 %) in patients with CD, with or
without related symptoms. The Japanese proposed diag-
nostic criteria for Crohn’s disease [39] refer to irregular-
shaped ulcers and aphthous ulcerations found in both the
upper and lower gastrointestinal tract as minor findings39.
Accordingly, to make a definitive or differential diagnosis
of CD, it is useful to explore lesions by using upper-gas-
trointestinal endoscopy and by examining biopsy samples
for histological evaluation (to check for the presence of
noncaseating epithelioid cell granuloma).
CQ9: What endoscopic findings are characteristic
of CD? [46, 47]
• Lower-gastrointestinal endoscopic findings character-
istic of CD include discrete or segmental lesions (so-
called skip lesions), a cobblestone-like appearance,
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longitudinal ulcers, irregular-shaped ulcers, multiple
aphthous ulcerations, abnormal narrowing and/or ste-
nosis, and fistulas (internal and/or external fistulas). B*
(Japan V, overseas VI; 9).
• Upper-gastrointestinal endoscopic findings characteris-
tic of CD include a bamboo joint-like appearance, a
notch-shaped appearance, cobblestone-like appearance,
multiple aphthous ulcerations, erosion, irregular-shaped
ulcers, bead-like protrusions, nodular folds, granular
mucous membrane, and stenosis. C1 (Japan V, overseas
VI; 8).
Comments
It was reported that lower-gastrointestinal endoscopic
findings make it possible to differentiate 89 % of CD cases
from UC among suspected cases of IBD [46]. Findings
helpful in differentiating CD from UC are discrete lesions,
cobblestone-like appearance, aphthous ulcerations and
longitudinal ulcers, and perianal lesions [47].
Frequently encountered upper-gastrointestinal lesions of
CD are a bamboo joint-like appearance in the stomach,
gastric and duodenal erosions and/or ulcers, and duodenal
notch-like protrusions and/or longitudinal erosions.
CQ10: Is examination of the entire gastrointestinal tract
necessary in the diagnosis of CD? [40, 41, 47]
• Examinations of the lower gastrointestinal tract (using
endoscopy or barium enema radiography) are almost
indispensable for making a diagnosis of CD. B* (Japan
VI, overseas VI; 9).
• Even after a definitive diagnosis has been made, it is
preferable to examine the patient using small-intestinal
contrast radiography and upper-gastrointestinal endos-
copy. C1 (Japan VI, overseas VI; 8).
Comments
For the definitive diagnosis of CD, use lower-gastrointes-
tinal endoscopy with biopsy for histopathological evalua-
tion before undertaking other investigations. Even after the
diagnosis is made, it is preferable to investigate the entire
gastrointestinal tract, using small-intestinal contrast radi-
ography and upper-gastrointestinal endoscopy, in order to
determine the disease type, as determination of the type
will contribute to the selection of the appropriate treatment
and scheduling of the follow up. In cases where the results
of a lower-gastrointestinal endoscopic examination do not
produce a definitive diagnosis, it is absolutely necessary to
explore lesions in the small intestine and the upper gas-
trointestinal tract [40, 41, 47].
If lesions are not found using small-intestinal contrast
radiography or upper- and lower-gastrointestinal endos-
copy despite clinical suspicions of CD, exploration of the
small-intestinal lesions using capsule endoscopy may be
useful in some cases; however, this procedure is not yet
approved for clinical use in Japan for suspected cases of
CD. The usefulness of small-intestinal endoscopy in the
diagnosis of CD has not been established clearly, although
it is useful in some cases of diagnostic difficulty.
II-5. Contrast radiography
CQ11: When is contrast radiography necessary to make
a diagnosis of CD? [47–49]
• As CD may be complicated with intestinal stenosis,
fistulas, abscess, and/or adhesions, the addition of bar-
ium enema radiography to colonoscopy would be
advisable. C1 (Japan VI, overseas VI; 8).
• Even if a diagnosis of CD is made by barium enema
radiography, small-intestinal contrast radiography is
valuable to determine the extent of the lesions and to
establish treatment strategies. C1 (Japan VI, overseas
VI; 8).
Comments
Barium enema radiography is helpful to overview the
entire colon and rectum, and small-intestinal contrast
radiography can be performed safely if there is no severe
stenosis in the colon. To explore small-intestinal lesions,
contrast radiography is still useful, with a sensitivity of
85–95 % and specificity of 89–94 % to detect typical
lesions of CD [47–49].
CQ12: Which findings of contrast radiography
are characteristic of CD? [49–52]
• Longitudinal ulcers (asymmetric sclerotic appearance),
cobblestone-like appearance, stenosis, aphthous ulcer-
ations, irregular-shaped ulcers, fissures, and fistulas are
typically found. B* (Japan V, overseas VI; 9).
Comments
A longitudinal ulcer is an ulcer 5 cm or longer that runs
along the longitudinal direction of the gastrointestinal tract
on the mesentery side in the small intestine and along the
teniae coli in the colon, varying in width from a wide band
to a thin line. Shortening of the mesentery side of the small
intestine due to longitudinal ulcers produces an asymmetric
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sclerotic appearance, which is found in approximately
84 % of CD cases [49–52].
A cobblestone-like appearance is where scattered polyp-
like protrusions are formed in an area of mucous membrane
surrounded by a longitudinal ulcer and with smaller ulcers
running transversely. It is assumed that mucosal edema,
shortening of mucosal muscle, inflammatory cell infiltra-
tion, and fibrosis produce such a distinctive feature [52].
II-6. Other imaging procedures
CQ13: How can imaging procedures such as CT
and abdominal ultrasonography (US) contribute
to making a diagnosis of CD? [53]
• CT and US are useful for evaluating the extent and
severity of gastrointestinal inflammation, and for the
detection of abscess formation. C1 (Japan VI, overseas
VI; 8).
Comments
CT and US can be used to assess intestinal inflammation,
based on thickening of the intestinal walls and the
increased density of surrounding fatty tissues. Contrast CT
and MRI are helpful in detecting abscess formation. CT
colonography, although useful in assessing lesions proxi-
mal to a stenosis, is not universally available [53].
II-7. Histopathological examination
CQ14: What pathological findings are characteristic
of CD? [52, 54]
• Findings for a definitive diagnosis of CD include: (1)
noncaseating epithelioid cell granuloma, (2) transmural
inflammation, (3) fissure, and (4) ulcers. C1 (Japan VI,
overseas VI; 8).
Comments
Abnormal alignment of crypts and basal cell plasmacytosis
are found in the biopsy specimen, and these are findings in
common with those of IBD. A key to differentiating CD
from UC is focal inflammation. Granuloma is composed of
such cells as epithelioid cells, macrophages, lymphocytes,
and multinucleate giant cells. Although noncaseating epi-
thelioid cell granuloma is a principal basis for a diagnosis
of CD, it is detected in 40–60 % of surgical specimens, and
in only 15–36 % of biopsy specimens [54]. Multiple biopsy
specimens for serial sections may improve the rate of
detection of granuloma. Note, however, that multinucleate
giant cells may be found in foreign-body granulomas, and
that noncaseating epithelioid cell granulomas may be found
in tuberculosis [52].
In transmural inflammation, focal aggregations, mainly
of lymphocytes, are found to be transmurally distributed
unevenly. Lymphangiectasis, edema, and fibrosis are also
found. Disproportionate inflammation, manifested more
strongly in the submucosa than in the lamina propria, is a
convincing key to the biopsy diagnosis of CD. Fissure
formation is a vertical tissue defect along a lymphatic duct.
II-8. Definitive diagnosis
CQ15: How can a definitive diagnosis be made? What
diagnostic criteria are used? [39]
• If CD is suspected based on medical interview, physical
examination, and laboratory test results, gastrointestinal
investigations should be conducted. C1 (Japan VI,
overseas VI; 9).
• The Japanese proposed diagnostic criteria for Crohn’s
disease [39] (Table 5) consist mainly of morphological
findings of the gastrointestinal tract. C1 (Japan VI; 8).
Comments
Among major findings, longitudinal ulcers in CD can be dif-
ferentiated from those in UC or ischemic colitis by the presence
of protrusions due to inflammatory edema. The cobblestone-
like appearance in CD involves dense protrusions of mucous
membrane of uneven sizes, large or small, surrounded by a
longitudinal ulcer and smaller ulcers. This appearance may be
seen in ischemic colitis, but in ischemic colitis the protrusions
are less dense and hyperemia is more intense.
CQ16: If a diagnosis of CD is not definitive, what
should be done? [54, 55]
• In indeterminate colitis where it is difficult to differ-
entiate CD from UC, choose treatment strategies for the
more suspected disease, observe progress with regular
check-ups, and make a definitive diagnosis as soon as
the features of one or the other disorder become dom-
inant. C1 (Japan VI, overseas VI; 8).
• If the diagnosis of CD is not definitive, as in patients
with only aphthous ulcerations, observe progress with
regular check-ups, and a definitive diagnosis of CD can
be made when morphological examinations fulfill the
criteria for the diagnosis. C1 (Japan VI, overseas VI; 8).
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Comments
The number of reports of indeterminate colitis (IC), which
has clinical and histopathological features of both UC and
CD and is thus difficult to differentiate from either of
these conditions, is increasing [54, 55]. IC accounts for
approximately 4 % of IBD cases in Japan [55]. Even after
intestinal resection, in approximately 5 % (range 1–20 %)
of cases, a definitive diagnosis cannot be made, because
of overlapping histopathological features [54, 55].
Although the usefulness of serum anti-Saccharomyces
cerevisiae (ASCA) and anti-neutrophil cytoplasmic anti-
body (ANCA) measurements has been reported, their
diagnostic accuracy for IC has not been established. At
present, serial observations with endoscopy and other
procedures are important, and a definitive diagnosis is
made when characteristic features of either UC or CD are
obtained (i.e., when the criteria for diagnosis of either one
are satisfied). After observing the progress of IC for
8 years, a definitive diagnosis of CD or UC was made in
80 % of cases [54]. Treatment strategies are decided with
a tentative diagnosis based on the clinical and imaging
features.
When CD is suspected but without a definitive diagno-
sis, as in patients with aphthous ulcers that show no lon-
gitudinal arrangement and patients who do not have
noncaseating epithelioid cell granuloma, regular follow up,
using laboratory test results and morphological examina-
tions is necessary to be able to make a definitive diagnosis
of CD when the criteria for the diagnosis are met. Use
mainly symptomatic treatments until a definitive diagnosis
is made. If morphological examinations cannot confirm the
diagnosis, but CD is suspected comprehensively by
symptoms and laboratory test results, treatments for CD
may be initiated, while observing the patient’s progress and
conducting follow-up examinations.




C. Noncaseating epithelioid cell granulomab
Minor findings
a. Irregular-shaped and/or quasi-circular ulcers or aphthous ulcerations found extensively in the gastrointestinal tractc
b. Characteristic perianal lesionsd
c. Characteristic gastric and/or duodenal lesionse
Definite
1. Major finding A or Bf
2. Major finding C, with minor finding a or b
3. All minor findings a, b, and c
Suspected
1. Major finding C, with minor finding c
2. Major finding A or B, but cannot be differentiated from ischemic colitis or ulcerative colitis
3. Major finding C onlyg
4. One or two minor findings
a In the small intestine, the ulcer occurs more commonly on the mesentery side
b The rate of detection of this granuloma is improved by creating serial sections. It is advisable that a pathologist familiar with the gastroin-
testinal tract examine a specimen of it
c In typical cases, the ulcers are arranged longitudinally, but this does not occur in some cases. It is necessary that they persist for at least
3 months. With regard to this condition, it is necessary to exclude enteric tuberculosis, intestinal Behc¸et’s disease, simple ulcer, nonsteroidal
anti-inflammatory drug (NSAID)-induced ulcers, and infectious enterocolitis
d These lesions consist of anal fissures, cavitating ulcers, anal fistulas, perianal abscesses, and edema-like anal skin tags. Preferably, colorectal
surgeons familiar with Crohn’s disease are consulted to examine such lesions, referring to the Atlas of findings by visual observation of lesions in
the anus of Crohn’s disease [38]
e These lesions have a bamboo joint-like appearance, with notch-like depressions. Preferably, specialists familiar with Crohn’s disease are
consulted to examine such lesions
f In cases with only longitudinal ulcers, it is necessary to exclude ischemic intestinal lesions and ulcerative colitis. In cases with only a
cobblestone-like appearance, it is necessary to exclude ischemic intestinal lesions
g It is necessary to exclude inflammatory diseases with granulomas such as intestinal tuberculosis
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II-9. Determination of severity
CQ17: How are the severity and activity of the disease
determined? [40, 56, 57]
• The severity and activity are usually determined on the
basis of clinical symptoms. C1 (Japan VI, overseas VI;
7).
• The IOIBD and CDAI can be used to quantify the
disease activity, but these indices are not easy to use in
daily clinical practice. C1 (Japan VI, overseas VI; 8).
Comments
The IOIBD score consists of nine clinical parameters and
hemoglobin, and it is a convenient index that is used in the
disease datasheet of the Japanese national CD registration.
Though the IOIBD data have a certain level of correlation with
the CDAI scores [40], the number of items showing correla-
tion is limited, and the IOIBD is not suitable for detailed
evaluation of the long-term progress of the disease. In Europe
and North America, the CDAI [40], in which eight indices are
calculated, is used as a standard index for the assessment of
disease activity; it is also used to assess treatment efficacy in
clinical studies in Japan. However, calculation of the CDAI
requires that clinical symptoms and laboratory test data are
available over the 7 days immediately before the day of cal-
culation. Thus, it is not suitable for use in daily clinical
practice. Although assessment of severity is important for
treatment, severity does not always correlate with disease
activity [56]. In some patients, particularly those with small-
intestinal lesions, the clinical symptoms are mild, and disease
activity is not reflected in the CDAI scores.
In selecting treatment options, comprehensive evalua-
tion should be made. The initial treatment might be mod-
ified during the follow-up period. A recent opinion
suggests that the disease pattern (whether the case is sus-
ceptible to fistulation or stenosis) and the mucosal healing
of gastrointestinal lesions should be evaluated.
The European Crohn’s and Colitis Organisation (ECCO)
has classified disease activity in the categories of mild,
moderate, and severe according to the criteria shown in
Table 6 [57].
III. General principles of treatment
III-1. Outline of treatment
CQ1: If a patient has a diagnosis of CD, what will
the treatments be, and how will this affect the patient’s
lifestyle? [56–60]
• In the active stage, the treatments are directed to induce
remission; once remission is induced, the treatments are
given to maintain remission for a prolonged period. B*
(Japan VI, overseas VI; 9).
• Therapeutic modalities include medical treatments,
such as drug therapies and nutritional therapies, and
surgical treatments. They are selected as monotherapy
or combination therapy. B* (Japan VI, overseas: VI 9).
• The majority of patients can live a normal daily life,
with regular school life or working hours. In patients
with severe or fulminant symptoms, or frequent
relapses, the patient needs to be hospitalized, or
requires surgical treatment, and faces dietary and
lifestyle restrictions. C1 (Japan VI; 8).
Comments
Repeated remissions and relapses are characteristic during
the course of CD. Because CD is not curable at present, the
goal of the treatment is to control disease activity and to
improve the QOL of the patient. For this purpose, it is
important to control the symptoms, to maintain nourish-
ment, and to prevent relapse or postoperative recurrence by
combining drug therapies, nutritional therapies, and surgi-
cal treatments [58].
Treatments are selected according to the sites of lesions,
the levels of inflammation, the disease pattern, the
responses to treatments in the past, and the presence or
absence of complications. Although there is abundant
evidence in regard to the efficacy of different treatments in
relation to disease severity or location, the patients should
be fully instructed about the disorder, and the treatment
should be chosen according to the social background and
environment of the patients, as well as the individual
pathological conditions [56–59].




Mild 150–220 None Slight rise
Moderate 220–450 No manifestation of complications such as bowel
obstruction
Clear rise No response to treatment for mild
CD
Severe [450 Bowel obstruction, abscess, and other features Great rise Poor treatment response
CDAI Crohn’s disease activity index, CRP C-reactive protein
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In mild to moderate cases, remission is sufficiently
attained with drug and/or nutritional therapies, and the
patient can live a normal daily life with maintenance
treatment and some attention to daily life. For moderate
cases, the patient needs to be hospitalized during periods of
relapse, but can otherwise live an almost normal life [60].
III-2. Consultation
CQ2: Should a CD patient be referred to a specialist
for the treatment? [21]
• On many occasions in the management of CD, con-
sultation with a specialist is necessary. B* (Japan VI,
overseas VI; 9).
• Consultation is required for nutritional therapy, anti-
tumor necrosis factor (TNF) therapy, failure to maintain
remission, and surgical treatment. B* (Japan VI,
overseas VI; 9).
Comments
Except for very typical cases, consultation with a specialist
should be considered for any diagnostic difficulty. If the
institution is not sufficient for diagnostic investigations, the
patient should be referred to a specialist to establish
the diagnosis and to determine the extent and severity of
the disease [21].
At the initial diagnosis of CD, consultation with a spe-
cialist is preferable for education and general guidance.
Quiescent cases can be managed by a general practitioner
for remission maintenance and follow up.
Steroid-dependency and the administration of immuno-
modulators or biologic agents are indications for consultation.
In cases of intestinal/extra-intestinal complications, the
patient should be referred to specialists in the relevant areas.
III-3. Hospitalization
CQ3: Under what circumstances should a CD patient be
hospitalized? [57, 61, 62]
• Consider hospitalization when the patient does not
improve on outpatient treatment. B* (Japan VI, over-
seas VI; 9).
Comments
If a patient does not improve with outpatient drug or
nutritional therapies, and has persistent symptoms such as
frequent diarrhea, abdominal pain, fever, and weight loss,
and/or elevated inflammatory markers, hospitalization
should be considered [57, 61]. In patients with stenosis
causing bowel obstruction and those with intra-abdominal
abscess formation, hospitalization and surgical treatment
should be considered [57]. According to a case series
study, a high proportion (50–80 %) of CD patients with
small-intestinal lesions require hospitalization/surgery as
the disease progresses [62].
III-4. Exercise and social activities
CQ4: Does a CD patient require rest and restriction
of social activities? [31, 60, 63, 64]
• Generally, patients do not require rest or restriction of
activities. C1 (Japan VI, overseas VI; 8).
• Patients in the active phase with severe abdominal
symptoms, a finding of systemic inflammation, and
exhaustion should avoid excessive exercise. C1 (Japan
VI; 8).
• In the active phase of the disease, patients face
restrictions of social activities, such as school or work,
due to treatment or hospitalization. B (Japan IVb; 8).
Comments
In the long-term progression of CD, the QOL of the patients is
generally well maintained. The number of patients with poor
QOL for whom social activities are significantly restricted due
to symptoms and/or treatment is limited [31, 63].
If remission is maintained, normal exercise, work, and
school attendance are expected. However, in the active
phase, too much exercise causing a heavy physical or
mental burden is to be avoided [31, 60]. There is no evi-
dence that bed rest or lifestyle restrictions contribute to the
maintenance of remission. Rather, some reports have
indicated that moderate exercise reduces CD disease
activity and mental stress [64].
III-5. Diet
CQ5: Is dietary therapy necessary for the treatment
of CD? [21]
• There are no specific dietary therapies to cure or
improve CD. C1 (Japan VI, overseas: VI; 9).
• For patients in the active phase, considerinflammation
in the gastrointestinal tract when selecting foods, . C1
(Japan VI, overseas VI; 8).
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• Do not allow the patient to take food orally in the
presence of severe inflammation or obstruction. C1
(Japan VI, overseas VI; 8).
Comments
Dietary therapy denotes management in which the amounts
of meals or food ingredients are adjusted, with the aim
being to overcome or alleviate a disease. Unlike findings
with hypertension, hyperlipidemia, and diabetes, no pri-
mary therapeutic effect of any dietary therapy in CD has
been scientifically proven. Dietary guidance or advice is
preferably minimal, such as cautions to avoid excessive
drinking and eating or stimulants.
Although the causes of CD are unknown, it is assumed
that some dietary factors are involved in the onset and the
persistence of inflammation. In many cases, the oral intake
of foods exacerbates the symptoms, and these patients have
usually had an unbalanced diet before the onset of the
disease; thus, it can be presumed that diet may have some
relationship to CD. In general, patients with inflammation
in the gastrointestinal tract are recommended to avoid fats,
stimulants, and dietary fiber. In CD patients, this recom-
mendation also means that the antigens in the diet are
reduced to keep the intestinal tract at rest.
Nutritional deficiency is often found in CD patients due
to various causes. When CD is diagnosed, the nutritional
condition of the patient should therefore be assessed, and
assessment should be carried out regularly during the
progress of the disease, with nutritional support being
provided according to the patient’s pathophysiological
condition [21].
CQ6: What kind of general dietary recommendations
should be made? [15, 60]
• Basic recommendations during the active phase include
having a low-fat, low-residue diet with low levels of
stimulants, and food high in protein and calories, to
improve the nutritional state while keeping the intesti-
nal tract at rest. C1 (Japan VI, overseas VI; 7).
• In the remission phase, no strict dietary restrictions are
necessary, but a low-fat diet is preferred. C1 (Japan IVb; 7).
• The response of the gastrointestinal tract to foods varies
considerably from person to person. Accordingly, indi-
vidual patients should avoid specific foods that make their
symptoms worse. C1 (Japan VI, overseas VI; 8).
Comments
Dietary guidance differs according to the individual and
their symptoms. Basically, no foods are absolutely
restricted; however, it is advisable that CD patients main-
tain an orderly and regular diet, and learn which foods
exacerbate their condition, and avoid such foods. Although
there is little evidence to show any relationship between the
diet and food ingredients and the disease activity of CD, a
Japanese case–control study has indicated that fats are a
risk factor for CD [15]. Low-fat, low-residue, high-protein,
and high-calorie foods are basic dietary suggestions for CD
[60]. When a patient undergoes a resection of the small or
large intestine, the diet should be considered according to
the region that has been resected.
As evidence is lacking for the effects of health food
products and popular supplements, and because their safety
has not been confirmed, they are not recommended.
III-6. Smoking
CQ7: Should a CD patient refrain from smoking?
[65–71]
• Upon diagnosis, the patient with CD should quit
smoking. B (overseas III; 8).
Comments
An analytical epidemiological study showed that smoking
was associated with the onset of CD [65]. It has also been
reported that in infants exposed to passive smoking this has
an adverse effect [66]. Case–control studies have indicated
that, after remission is induced by medical or surgical
treatments, the relapse rates and requirements for surgery
are higher among smokers [67–69]. An interventional trial
showed that a group that continued to refrain from smoking for
more than 1 year had a better prognosis than continuos smoker
[70]. With these lines of evidence, smoking cessation is rec-
ommended for those who have a diagnosis of CD.
A multivariate analysis of the factors influencing the
therapeutic effect of infliximab concluded that smoking
was not an independent factor influencing the therapeutic
effect; however, for the above-mentioned reasons, patients
with CD are recommended to quit smoking [71].
III-7. Alcohol drinking
CQ8: Should a CD patient refrain from drinking
alcohol? [60]
• It is not necessary to recommend to every patient with
CD that they refrain from drinking alcohol. However, it
is preferable to avoid excessive drinking and to stop
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drinking when the disease is in the active phase. C1
(Japan VI, overseas VI; 7).
Comments
There is little evidence that drinking alcohol affects the
disease activity or progression of CD. However, alcohol
may injure the mucosa of the intestinal tract and exacerbate
the symptoms of CD. In the remission phase, drinking
modest amounts of alcohol is acceptable, but it would be a
good practice to advise patients to restrain themselves
when drinking, as some people tend to drink excessively.
IV. Therapeutic intervention (Fig. 2)
IV-1. Treatment options
CQ1: What are the treatment options for CD,
and in what combinations? [56–58]
• Treatment strategies include drug therapies, nutritional
therapies, surgical therapies, and other modalities.
Select the most appropriate treatments according to the
severity, extent of the lesion, and disease pattern. C1
(Japan VI, overseas VI; 9).
• Initially, or in a relapse, apply drug therapies and
nutritional therapies as monotherapy or in combination,
with the aim being to induce remission. C1 (Japan VI,
overseas VI; 8).
• In patients with intestinal stenosis, fistulas, abscesses,
and/or perianal lesions, or in cases that are resistant to
medical treatment, consider surgical treatment. C1
(Japan VI, overseas VI; 8).
• Once remission is induced, maintain remission using
drug therapies (5-aminosalicylic acid [5-ASA] prepa-
rations, immunomodulators, anti-TNF agents), and/or
nutritional therapies as monotherapy or in combination.
C1 (Japan VI, overseas VI; 9).
Comments
At present, no treatments can completely cure CD. The
purposes of treatment are to control the disease activity and
to improve the QOL of the patients; in other words, the aim
Anal lesions (anal fistulas)
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is to maintain remission for as long as possible. For these
purposes, select drug, nutritional, and surgical therapies as
indicated to attenuate symptoms, to maintain nourishment, and
to prevent relapse. Patients should be fully instructed about the
disorder, and the treatment should be chosen according to the
social background and environment of the patients, as well as
the individual pathological conditions [56–58].
Both drug and nutritional therapies for CD inevitably
have adverse effects. However, the benefit of each thera-
peutic modality outweighs the risk. Some therapies are safe
in the short term, but may produce adverse effects in the
long term. It is desirable that nutritional therapies and drug
therapies be used to supplement each other.
IV-2. Steroids
CQ2: When are steroids indicated? What kinds
of benefits and harms are expected? [21, 59, 72–74]
• Steroids possess potent anti-inflammatory effects. They
are effective in inducing remission, but ineffective for
maintaining remission. A (Japan V; overseas I; 8).
• Steroids may cause adverse effects, particularly with long-
term administration. Thus, steroids should be administered
mainly to induce remission, and thedosageshould be tapered
until they are discontinued. C1 (Japan VI, overseas VI; 8).
• Steroids are indicated for patients with moderate to
severe disease activity, as well as for mildly active
disease that is refractory to 5-ASA preparations. A
(Japan VI, overseas II; 8).
Comments
Randomized controlled trials were conducted in Europe and
North America in the 1970s and 1980s to evaluate the effect of
steroids, and a meta-analysis showed their efficacy in inducing
remission [72]. However, efficacy in maintaining remission
was not shown [73]. In the randomized controlled trials
adopted in the meta-analysis, steroids were shown to be more
efficacious than placebo or 5-ASA preparations in cases of
disease of varying severity, with CDAI scores ranging from
150 to 450 [72]. However, the indication for steroids has
changed with the emergence of anti-TNF agents.
While steroids have potent anti-inflammatory effects, they
may cause adverse effects such as compromised immune
functions, impaired glucose tolerance, delayed wound healing,
and osteoporosis. Furthermore, they are not effective in
maintaining remission. Accordingly, steroids should not be
administered for prolonged periods [21]. In cases where 5-ASA
preparations cannot induce remission, oral administration of
steroids is recommended. When administering steroids, the
dosage should be tapered down to eventual termination irre-
spective of the response [21, 56, 58, 59]. Daily administration
of 9 mg budesonide (not yet approved in Japan), which is a
steroid with reduced systemic side effects, is effective in
inducing remission in mild to moderate cases [56, 57, 74].
IV-3. 5-ASA preparations
CQ3: When are 5-ASA preparations indicated? What
kinds of benefits and harms are expected? [75–77]
• 5-ASA preparations have clinical efficacy in active CD.
A (overseas I; 8).
• During the remission phase, 5-ASA preparations have a
limited effect on maintaining remission, but harm is
minimal. A (overseas I; 8).
Comments
According to a meta-analysis of randomized controlled trials, in
cases with mild to moderate activity, mesalazine 4 g/day sig-
nificantly reduced CDAI scores compared with placebo [75].
Another meta-analysis performed to evaluate the effi-
cacy of 5-ASA preparations in remission maintenance did
not show any difference between the 5-ASA preparations
and placebo [76]. Another meta-analysis suggested that
5-ASA preparations were significantly efficacious in
maintaining remission in CD [77].
Because the safety profiles of 5-ASA preparations are
good, these preparations are frequently used in actual
practice. They are also administered in the long term in
many patients for the purpose of maintaining remission.
IV-4. Immunomodulators
CQ4: When are immunomodulators indicated? What
kinds of benefits and harms are expected? [78, 79]
• Azathioprine (AZA) and 6-mercaptopurine (6-MP)* are
effective in inducing remission in CD, but their adverse
effects should be noted. A (overseas I; 8) *Not covered
by Japanese public health insurance.
• AZA is effective in maintaining remission in CD, and
has a steroid-sparing effect. A (overseas I; 9).
Comments
Daily administration of 2.0–3.0 mg/kg AZA, and daily
administration of 50 mg (or of 1.5 mg/kg) 6-MP, are both
useful in inducing remission in CD in the active phase [78].
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Daily administration of 1.0–2.5 mg/kg AZA in patients
with quiescent CD is effective to prevent relapse for
6 months to 2 years. The steroid-sparing effect of immu-
nomodulators is useful for withdrawing steroids. However,
it is not clear whether AZA has a long-term effect on
remission maintenance [79]. A higher dose (2.5 mg/kg
daily) of AZA has a more potent effect on remission
maintenance than a lower dose (1.0 or 2.0 mg/kg daily).
Immunomodulators are slow-acting drugs, and may cause
serious side effects (e.g., myelosuppression and pancreati-
tis.); therefore, the benefits and harms of these drugs should
be carefully considered. Because Japanese have a lower
ability to metabolize these drugs than Caucasian, Japanese
patients are particularly susceptible to the dose-dependent
adverse effects of immunomodulators. Smaller doses (AZA
50–100 mg daily) than those used overseas are usually
administered in Japan.
IV-5. Anti-TNF agents
CQ5: When are anti-TNF agents indicated? What kinds
of benefits are expected? [80–85]
• Anti-TNF agents are effective to induce remission. A
(overseas I; 9).
• In CD patients brought into remission by anti-TNF
agents, these agents are also effective for fistula-closure
and remission maintenance. A (overseas I; 8).
• When infliximab has not been successful, adalimumab
may be effective in inducing remission and attenuating
symptoms. A (overseas I; 8).
Comments
Adalimumab, a humanized anti-TNF-a monoclonal anti-
body agent, was approved in Japan for the treatment of CD
in 2010, in addition to infliximab.
A randomized controlled trial on the remission induction
effect of infliximab in patients with active CD indicated
that a single administration of 5 mg/kg was efficacious in
inducing remission in CD [80]. Moreover, 5 mg/kg or
10 mg/kg of infliximab given every 8 weeks to patients
with CD in remission brought about by infliximab was
efficacious in maintaining remission and fistula closure [81,
82]. In clinical practice, 5 mg/kg of infliximab is admin-
ister at week 0, week 2, and week 6, and then at intervals of
8 weeks. If the required effect is not obtained, consider
other treatments instead of simply continuing this agent.
A randomized controlled trial on the remission induction
effect of adalimumab indicated that two subcutaneous
administrations of 80/40 or 160/80 mg of this drug in CD
patients with moderate disease activity showed a signifi-
cant remission induction effect at week 4 [83]. A trial on its
remission maintenance effect indicated that administration
of 40 mg subcutaneously at intervals of 2 weeks or 1 week
showed a significant remission maintenance effect at week
56 [84]. In clinical practice, 160 mg of adalimumab is
initially administered subcutaneously, followed by 80 mg
2 weeks later, and then 40 mg at intervals of 2 weeks, in
order to maintain remission.
In patients with active CD in whom infliximab was
unsuccessful (due to intolerance or symptoms persisting
after its administration), adalimumab had a significant
effect on remission induction and had attenuated symptoms
at 4 weeks after administration [85]. That trial, however,
did not directly compare adalimumab with infliximab, nor
did it deal with remission maintenance.
CQ6: What harms are anticipated with the use
of anti-TNF agents? [81, 86–92]
• Cases of serious infections and cases of opportunistic
infections have been reported among patients who
received infliximab or adalimumab. B (overseas IVa;
8).
• Infliximab increases the chance of tuberculosis infec-
tion (including reactivation). B (overseas IVa; 8).
• The occurrence of malignant tumors, including lym-
phoma, was reported among patients who received
infliximab. B (overseas IVa; 8).
• The incidence of cancer in general among patients who
received adalimumab does not seem to be different
from that in the general population. C1 (overseas V; 8).
Comments
A meta-analysis of studies of infliximab indicated no
significant difference in the incidence of serious infec-
tions between the infliximab and placebo groups [81]. A
multivariate analysis of a prospective study of more than
6,000 people in the TREAT Registry suggests that the
causes of increases in serious infections in CD patients are
not related to the use of infliximab, but to steroids, nar-
cotic analgesics, and the severity of the disease [86]. In
addition, the risk of opportunistic infection in patients
with IBD was shown to increase due to the combined use
of multiple immunomodulators with infliximab and old
age [87].
However, infliximab is known to increase the reactiva-
tion and incidence of tuberculosis infection. In addition, it
is known that it increases extra-pulmonary lesions and
disseminated tuberculosis [88]. Screen patients with CD for
tuberculosis infection before administering infliximab, and
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consider the prophylactic administration of anti-tubercu-
losis drugs, as necessary.
Analysis of the TREAT Registry indicated a worsening
of intestinal stenosis in those who received infliximab, but
a multivariate analysis concluded that the only risk factors
were the duration and severity of the disease, small-intes-
tinal lesions, and the initiation of steroid therapy [89].
Although few studies have indicated a relationship between
infliximab and the occurrence of stenosis, patients should
be informed of the risk of stenosis after taking infliximab,
and surgeons should be notified if a CD patient is receiving
this drug.
A further study with the TREAT Registry indicated a
significant difference in the incidence of malignant tumors,
including lymphoma, between groups with and without the
use of infliximab [90]. A multicenter matched-pair study in
Italy showed similar results [91]. However, the observation
periods in these two studies were not long enough to reach
definitive conclusions. Nevertheless, patients should be
notified of the risk before infliximab treatment is initiated.
Adverse effects over a period of 10 years were reported in
20,000 patients from 36 clinical studies on six immune-
mediated diseases [92]. In patients with CD, abscesses in the
abdominal cavity or the gastrointestinal tract and opportu-
nistic infections were found, but in general, no risk of major
infections was found. The incidence of cancer in these CD
patients was equivalent to that in the general population.
The harmful effects noted above are considered to be
common to all anti-TNF agents.
IV-6. Antimicrobial drugs
CQ7: When are antimicrobial drugs indicated, and what
kinds of benefits and harms are anticipated? [93–97]
• Antimicrobial drugs* are sometimes effective in
attenuating the clinical symptoms of CD. A (overseas I;
8). *Antimicrobial drugs are not covered by the Japa-
nese public health insurance system when used for the
treatment of CD.
• These drugs are more effective for colonic lesions than
for small-intestinal lesions. A (overseas II; 8).
Comments
In some cases, antimicrobial drugs such as metronidazole
and ciprofloxacin are used for the treatment of CD. Mul-
tiple randomized controlled studies have been conducted to
evaluate the efficacy of antimicrobial drugs for treating
active CD, and the drugs showed efficacy in attenuating the
clinical symptoms [93–96]. They were more efficacious for
colonic lesions than for small-intestinal lesions [96].
Another report indicated that the administration of anti-
microbial drugs was efficacious in preventing the postop-
erative recurrence of CD [97]. However, the indications
and the specific treatment strategies for antimicrobial
therapies for CD have not yet been established.
When antimicrobial drugs are used for a long period of
time, caution should be exercised regarding potential
adverse effects. Metronidazole, in particular, may cause
peripheral neuropathy.
IV-7. Enteral nutriton
CQ8: When is enteral nutrition indicated, and what
kinds of benefits and harms are expected? [98–105]
• The efficacy of enteral nutrition for inducing remission
in active CD is equivalent or slightly inferior to that of
corticosteroids. A (Japan III, overseas I; 8).
• Elemental diet therapy is effective in maintaining
remission in CD. A (Japan II; 8).
• Although enteral nutrition is safe, maintenance of the
patient’s acceptance is often difficult. C1 (Japan VI; 8).
Comments
The results of several randomized controlled studies have
indicated that the efficacy of enteral nutrition for remission
induction in active CD is equivalent or slightly inferior to
that of corticosteroids [98–102]. A Japanese report indi-
cated that enteral nutrition with an elemental diet had a
higher rate of remission induction than prednisolone and
was particularly effective for attenuating intestinal lesions
[102]. This therapy is safer than corticosteroids.
Enteral nutrition is effective for the maintenance of
remission. It was reported that enteral nutrition with an
elemental diet for half of the total intake of calories was
efficacious in maintaining remission [103]. It was also
reported that continuing an elemental diet of 30 kcal per
kilogram per day was efficacious in preventing CD relapse
[104, 105]. However, it is frequently difficult to continue
enteral nutrition for an extended period because its
acceptability to the patient decreases.
CQ9: Are there differences in the therapeutic effect
between oligomeric and polymeric nutrients?
[98, 99, 106, 107]
• There are no significant differences between oligomeric and
polymeric nutrients in terms of their efficacy in remission
induction for active CD. A (Japan III, overseas I; 7).
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Comments
Oligomeric nutrients are enteral formulas which have
amino acids and oligopeptides as a nitrogen source, with a
lowcontent of fats, and these formulas are therefore easily
digested and assimilated. Among oligomeric nutrients, an
elemental diet has amino acids as a nitrogen source, and
contains little fat. Polymeric nutrients have proteins as a
nitrogen source and contain some fats. Polymeric nutrients
contain various nutrients in a good balance, and are easily
taken orally. Many randomized controlled studies have
been conducted to examine the differences among various
enteral nutrients in terms of their therapeutic efficacy for
active CD. The results have indicated no significant dif-
ferences in the effect of remission induction between
oligomeric and polymeric nutrients [98, 99, 106, 107]. In
Japan, there are some opinions that oligomeric nutrients are
clinically superior to polymeric nutrients.
CQ10: When is it necessary to administer enteral
nutrients through a nasogastric tube?
• A nasogastric tube is necessary in cases where enteral
nutrients should be given at a fixed rate, the oral intake
of such nutrients is difficult, or such nutrients need to
be given to patients at home during sleep at night. C1
(Japan VI, overseas VI; 8).
Comments
Enteral nutrients for patients with CD are taken orally, or
through a nasogastric tube inserted into the stomach or
duodenum. Unpalatable oligomeric nutrients are difficult
to take orally, and in many cases are given through a
nasogastric tube. Enteral nutrient feeding through a
nasogastric tube at a fixed rate, using an enteral feeding
pump, causes fewer side effects (such as diarrhea or
abdominal pain) than orally taken enteral nutrients. For
home enteral feeding, it is possible to give enteral nutri-
ents to a patient through a nasogastric tube at night, while
the patient is sleeping.
IV-8. Parenteral nutrition
CQ11: When is parenteral nutrition indicated,
and what kinds of benefits and harms are expected?
[58, 107–110]
• Total parenteral nutrition (TPN) is indicated for
patients with active CD who have serious malnutrition,
frequent diarrhea, and/or a critical disease state with
extensive small-intestinal lesions, or in patients who
have severe stenosis in the intestinal tract, fistulas,
abscess formation, massive hemorrhage, and/or severe
perianal lesions. The patient must be fasting when
parenteral nutrition is administered. C1 (Japan VI,
overseas VI; 8).
• Total parenteral nutrition (TPN) is efficacious in
inducing remission in active CD, and has a therapeutic
effect equivalent to that of enteral nutrition. B (Japan
III, overseas III; 8).
• When carrying out TPN, watch for complications such
as sepsis and hepatic disorders. C1 (overseas V; 8).
Comments
The indications for TPN through a central venous line are
described in the Proposed revision of the clinical practice
guidelines for Crohn’s Disease published by Research
Group of Intractable Inflammatory Bowel Disease subsi-
dized by the Ministry of Health, Labour and Welfare of
Japan [58]. However, in practice, it is necessary to select a
feeding method according to the individual’s condition.
The results of several randomized controlled studies have
shown that TPN, among other parenteral feeding methods,
has a remission induction effect for active CD equivalent to
that of the enteral feeding of elemental nutrients [107, 108].
TPN can also attenuate intestinal lesions [108, 109]. When
the CD patient’s condition becomes stable on TPN, the
TPN can be switched to enteral feeding.
If TPN is provided through a central venous line,
catheter-related complications such as sepsis and hepatic
disorders could occur. Particularly in patients undergoing
parenteral nutrition at home through a central venous line,
an infected feeding port is likely to progress to sepsis
[110].
IV-9. Cytapheresis
CQ12: When is cytapheresis indicated, and what kinds
of benefits and harms are expected? [111]
• Cytapheresis is indicated in patients with active CD
with colonic involvement in whom drug and/or nutri-
tional therapies are ineffective or inapplicable; the
addition of granulocyte-monocyte apheresis (GMA)
may accelerate induction of remission. C1 (Japan V; 7).
Comments
Cytapheresis has become an established therapeutic
modality for UC in Japan. For CD, the effects of GMA in
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combination with other therapies were studied in 21 cases
refractory to existing drug and/or nutritional therapies. The
results showed remission (i.e., CDAI less than 150) in
27.8 %, and improvement (i.e., reduction of CDAI by 50 or
more) in 16.7 % [111]. GMA was approved for clinical use
in CD with colonic lesions in Japan in 2010. Although
some adverse events, such as headache, dizziness, palpi-
tation, and minor nonspecific abnormal laboratory test
results have been reported, these therapies are generally
considered to be safe.
IV-10. Surgical treatment
CQ13: What kind of benefits and harms are expected
with surgical treatment? [112–114]
• Surgical treatment for the complications of CD is
expected to attenuate the symptoms and improve the
QOL. B (overseas IVa; 9).
• Surgical treatment reduces the doses of therapeutic
drugs and thus the possibility of adverse effects. C1
(Japan V, overseas IVa; 7).
• Surgical treatment involves the risk of postoperative
complications such as short-bowel syndrome and
anastomotic leaks. C1 (Japan V, overseas V; 8).
Comments
There are no therapies that can cure CD completely. The
purpose of surgical treatment is to attenuate the symptoms due
to complications that are the causes of the patient’s disability,
and to improve the patient’s QOL [112]. If the symptoms are
attenuated, the doses of therapeutic drugs such as steroids can
be reduced, thus preventing possible adverse effects (such as
growth retardation) [113]. However, reoperation becomes
necessary in some cases (the rate of reoperation in Japan was
reported to be as high as 28–30 %) [114]. Short-bowel syn-
drome due to repeated bowel resections can compromise the
patient’s QOL; resection should therefore be kept to the
minimum necessary.
IV-11. Endoscopic treatment
CQ14: When is endoscopic balloon dilation indicated,
and what kinds of benefits and harms are expected?
[115, 116]
• Endoscopic balloon dilation is indicated for benign
stenosis with bowel obstruction in the gastrointestinal
tract without accompanying deep ulcers or fistulas. C1
(Japan VI, overseas VI; 7).
• This therapy may alleviate bowel obstruction and may
avoid a surgical operation. C1 (Japan V, overseas V; 8).
• Care must be taken with regard to complications such as
perforation or restenosis. C1 (Japan V, overseas V; 9).
Comments
The major endoscopic treatment for CD is endoscopic
balloon dilation (EBD). In CD, EBD is indicated for benign
stenosis of comparatively short length with few flexures
producing clinical features of bowel obstruction, without
deep ulcers or fistulas. Accordingly, it is necessary to
employ endoscopy or contrast imaging to observe the ste-
nosis well before EBD is performed. The effectiveness of
EBD for CD has been reported from many medical insti-
tutions in Japan and overseas [115, 116]. It is particularly
effective for stenosis of a comparatively short length, such
as 4 cm or less [115]. The incidence of complications
involved in EBD was 2 %, and perforation accounted for
most of the cases [116]. Other than perforation, care must
be taken with regard to hemorrhage, fistulas, abscess for-
mation, and further restenosis.
V. Active phase treatment
V-1. Mild to moderate
CQ1: How is treatment initiated for mildly
to moderately active CD? [56, 75, 98, 99, 102,
117–124]
• Administer salazosulfapyridine (SASP) in patients with
mildly to moderately active CD with colonic lesions. A
(overseas II; 8).
• SASP is not effective for small-intestinal lesions. B
(overseas III; 8).
• The effect of 5-ASA preparations is limited, but they
lack serious side effects and are easy to administer. In
practice, they are often chosen as a first-line drug. A
(overseas I; 8).
• Daily administration of 1,000 mg ciprofloxacin* is
expected to have an effect similar to that of 5-ASA
preparations for colonic lesions in CD. B (overseas III;
7) *Not covered by Japanese public health insurance
for treatment of CD.
• The remission induction effect of enteral nutrition for
active CD is equivalent or slightly inferior to that of
corticosteroids. A (Japan III, overseas I; 8).
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Comments
As described in section II-9, there are no practical criteria to
determine the severity of CD, and thus it is determined on the
basis of a comprehensive assessment of clinical findings [56].
In these guidelines, mild to moderate cases are assumed to be
those in which the patient is capable of visiting a hospital on an
outpatient basis and of taking food orally, without findings
including dehydration, fever, abdominal tenderness, bowel
obstruction, or weight loss of 10 % or more [56].
A meta-analysis and several randomized controlled trials
have shown that SASP is effective for colonic lesions in mildly
to moderately active CD [117, 118], but that it is not effective for
small-intestinal lesions [119]. Some studies have also shown
that mesalazine is effective for CD [75, 120–122]. A recent
meta-analysis indicated that the CDAI score in the mesalazine
group was significantly reduced in comparison with that in the
placebo group [119]. In Japan, where treatment options are
limited, mesalazine is widely used for ileal and colonic lesions
because of its safety profile and ease of administration.
A randomized controlled trial has indicated that for
mildly to moderately active CD, 1 g ciprofloxacin admin-
istered daily has an effect similar to that of 4 g mesalazine
administered daily [123].
Meta-analyses that compared enteral nutrition with ste-
roid therapy concluded that steroids were more efficacious
[98, 99]. However, a randomized controlled small-size
study has indicated that nutritional therapy using elemental
nutrients has an effect of remission induction similar to that
of steroids (prednisolone 0.5 mg/kg daily), and provides
better nutritional status than steroids [124]. Furthermore, a
Japanese report indicated that enteral feeding of elemental
nutrients exhibited a higher rate of remission induction
than prednisolone treatment, particularly for intestinal
lesions [102]. In Europe and North America, budesonide, a
steroid with reduced systemic adverse effects, is used for
lesions in the ileum to the right side of the colon. Budes-
onide exhibited a higher rate of remission induction than
mesalazine.
V-2. Moderate to severe
CQ2: How is treatment initiated for moderately
to severely active CD? [56, 73, 111, 119, 125–128]
• Administer oral steroids (prednisolone, approximately
40 mg daily). B (overseas III; 8).
• In cases where steroids are not effective, consider
administering an anti-TNF agent. A (overseas II; 8).
• The remission induction effect of enteral nutrition for
active CD is equivalent or somewhat inferior to that of
corticosteroids. A (Japan III, overseas I; 8).
• In active CD with colonic lesions for which drug and/or
nutrition therapies are ineffective or inapplicable, the
addition of GMA may be helpful. C1 (Japan V; 7).
Comments
In these guidelines, moderate to severe cases are assumed
to be those in which therapies for mild to moderate cases
are not effective, or those in which the patient exhibits
symptoms that include weight loss of 10 % or more, ane-
mia, abdominal pain, and/or nausea/vomiting without
bowel obstruction [56].
Randomized controlled trials have shown that steroids
are efficacious in inducing remission in CD [73, 119].
However, steroids are not effective in maintaining
remission [73]. In patients in whom symptoms have
worsened during the tapering of steroids, or those in
whom there was a relapse shortly after withdrawal from
steroids, or in those with repeated relapses, consider using
an immunomodulator such as AZA or 6-MP in combi-
nation with steroids. In patients in whom AZA or 6-MP
cannot be used because of adverse effects, methotrexate
(MTX) is considered to be effective and is used overseas
[125, 126].
Anti-TNF agents, both with single administration and
with scheduled successive administrations, were shown to
be efficacious in cases refractory to steroids and/or im-
munomodulators [127, 128].
The addition of GMA was approved for clinical use in
Japan in 2010 for active CD with colonic lesions not
responsive to existing drug and/or nutrition therapies [111].
V-3. Severe to fulminant
CQ3: How is treatment initiated for severe to fulminant
CD? [56, 129]
• The patient is generally hospitalized; as necessary;
consider complete fasting, infusion of fluid, and/or
blood transfusion, and administer an antimicrobial drug
if the patient shows signs of infection. C1 (Japan VI,
overseas VI; 8).
• Exclude infections, and intravenously administer ste-
roids (prednisolone equivalent to 40–60 mg daily). C1
(Japan VI, overseas VI; 8).
• In cases resistant to steroids, consider administering an
anti-TNF agent. C1 (overseas V; 8).
• In cases where the patient’s general condition is poor,
or unresponsive to medical therapies, consult with
surgeons at an early opportunity. C1 (Japan VI,
overseas VI; 8).
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Comments
In these guidelines, severe to fulminant cases are assumed
to be those in which the patient’s symptoms persist after
oral administration of steroids, or those in which the patient
presents with high fever, persistent vomiting, bowel
obstruction, rebound tenderness, cachexia, and/or abscess
[56].
In general, the patient should be hospitalized to receive
intensive general supportive care. Orally administered
steroids are not as well assimilated as intravenous steroids,
and intravenous administration is advantageous in terms of
pharmacokinetics [129] and preferred for severe cases.
For fulminant cases not responsive to other medical
treatments, there is only limited evidence on the effects of
anti-TNF agents; however, they can still be a treatment
option. They should be used only when the presence and/or
risk of infectious complications such as abscesses are ruled
out. Severe cases in which the patient has unstable hemo-
dynamics, or those with peritoneal irritation, may be indi-
cations for surgical treatment, and therefore it is desirable
to consult with surgeons at an early opportunity.
V-4. Therapies according to disease extent
CQ4: Are different therapies used for lesions
in the small intestine, the colon, and both? [117, 118]
• Treatment options vary according to the disease extent.
C1 (Japan VI, overseas VI; 8).
• SASP is effective only for colonic lesions. A (overseas
II; 8).
• Antimicrobial drugs* are more effective for colonic
lesions than for small-intestinal lesions. B (overseas III;
8). *Not covered by Japanese public health insurance
for treatment of CD.
• Enteral nutrition is more effective for small-intestinal
lesions than for colonic lesions. A (Japan III, overseas
I; 8).
Comments
Consideration of the mechanisms and sites of action of
therapeutic drugs for CD indicates the appropriate use of
these drugs depending on the sites of the lesions, and it is
actually confirmed in some cases. SASP is effective only
for mild colonic lesions [117, 118]. Antimicrobial drugs,
particularly metronidazole, are known to be generally
effective for colonic and perianal lesions. Enteral nutrients
are significantly more effective for small-intestinal lesions
than for colonic lesions. Mesalazine is effective for both
small-intestinal and colonic lesions; and systemic steroids,
immunomodulators, and anti-TNF agents are not selective
with respect to lesion sites.
CQ5: What is the treatment for CD lesions in the upper
gastrointestinal tract? [56, 57]
• In cases of CD with upper-gastrointestinal lesions,
administer a proton pump inhibitor (PPI).* C1 (over-
seas VI; 7) *Not covered by Japanese public health
insurance for treatment of CD.
• Administer steroids and/or immunomodulators, such as
AZA or 6-MP, as necessary. C1 (overseas VI; 7).
• In cases refractory to steroids, consider administering
anti-TNF agents. C1 (overseas: VI; 8).
• In patients with upper-gastrointestinal lesions with
bowel obstruction, consider endoscopic dilation or
surgical treatment. C1 (overseas VI; 8).
Comments
Evidence is not sufficient with regard to the treatment for
upper-gastrointestinal lesions in active CD. PPIs are often
used for inflammatory lesions in the upper gastrointestinal
tract, in combination with other therapies, as in the treatment
for lesions at other sites [56, 57]. 5-ASA preparations in their
original forms do not act on the mucosa of the upper gastro-
intestinal tract, and therefore attempts have been made to
administer these agents orally by crushing and grinding the
tablets. However, the effectiveness and safety of these prep-
arations have not been sufficiently studied.
V-5. Perianal lesions
CQ6: What is the treatment for the perianal lesions
of CD? [36, 82, 130–132]
• Treat the intestinal lesions first, and wait to see if the per-
ianal lesions are attenuated. C1 (Japan VI, overseas VI; 8).
• Anti-TNF agents are effective as medical therapy for
anal fistulas. A (overseas II; 8).
• Antimicrobial drugs and immunomodulators are effec-
tive therapies for anal fistulas. A (overseas I; 8).
• The Seton procedure is an effective surgical treatment
for anal fistulas. In severe cases, consider a stoma. B
(Japan V, overseas V; 9).
Comments
Perianal lesions in CD include primary lesions (fissures and
cavitating ulcers), ulcerated piles with longitudinal ulcers,
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and secondary refractory lesions (perianal abscesses, anal
fistulas). In patients with perianal lesions specific to CD,
first employ medical therapies and/or surgical treatment for
the intestinal lesions, and wait to see if the perianal lesions
are attenuated. Among the secondary perianal lesions in
CD, the Seton procedure is effective for anal fistulas; for
common lesions, use ordinary treatments [130, 131]. An
overseas randomized controlled trial indicated that an anti-
TNF agent was effective for anal fistulas [82]. Anti-TNF
agents should be used after confirmation that any infection
is under control. There are no randomized controlled
studies on antimicrobial drugs (such as metronidazole) for
perianal lesions; however, limited evidence and clinical
experience indicate that these drugs have some efficacy.
For immunomodulators (such as AZA), several random-
ized controlled trials and meta-analyses have shown
effectiveness for anal fistulas [36, 132].
V-6. Refractory cases
CQ7: What is the treatment for cases refractory
to various medical treatment? [57, 133]
• Consider surgical treatment in cases refractory to
medical treatment without attenuation of complica-
tions. B* (Japan VI, overseas VI; 9).
• The indication for surgical treatment should be deter-
mined with mutual communications among the gastroen-
terologist, the surgeon, and the patient. B* (Japan VI; 9).
Comments
Medical treatment is the primary therapy for CD, and surgical
treatment remains as secondary. However, in cases refractory to
medical treatment, in which the patient has extremely impaired
QOL, with serious adverse reaction to drugs, or with a fibrous
stenosis not expected to be improved by medical treatment,
surgical treatment should be considered [57, 133]. The indication
for the surgical treatment should not be determined only by the
surgeon, but by thorough discussions involving the relevant
healthcare providers together with the patient.
V-7. Fistulas
CQ8: What is the treatment for fistulas? [82, 132, 134]
• Immunomodulators are effective for treating fistulas, but
their onset of the action is delayed. A (overseas I; 8).
• Anti-TNF agents are effective for treating fistulas. A
(overseas II; 9).
• Surgical treatment is indicated in patients with internal
fistulas causing severe malabsorption. B (Japan VI,
overseas VI; 8).
• Consider surgical treatment for fistulas with abscess
formation. B*(Japan VI, overseas IV:9).
Comments
Some cases of CD are complicated with internal fistulas
such as intestinal fistulas and external fistulas such as
intestinal-cutaneous fistulas. No consensus has been
reached with regard to either treatments for fistulas without
symptoms or treatments for internal fistulas [134].
As a medical treatment for fistulas, a meta-analysis of
overseas randomized controlled studies has indicated that
immunomodulators are effective [132], although the onset
of action of these drugs is delayed. An overseas large
randomized controlled study (ACCENT II) demonstrated
that infliximab was useful [82]. A study of the effect of
adalimumab on remission maintenance showed a signifi-
cant effect in closing external fistulas completely at week
26 and week 56.
Consider surgical treatment in patients in whom medical
therapies have been unsuccessful. The indications for sur-
gery include patients with internal fistulas causing severe
malabsorption, patients in whom fistulas are spread over a
broad area in the healthy bowel, patients with repeated
urinary tract infections, patients with external fistulas with
excessive leakage of intestinal juices, and patients with
painful perianal external fistulas complicated with abscess
formation [134].
V-8. Stenosis
CQ9: What is the treatment for an intestinal stenosis
due to CD? [115, 135, 136]
• Administer steroids in patients with severe inflamma-
tion. C1 (Japan VI, overseas VI; 7).
• Consider endoscopic dilation in patients in whom there
has been no improvement with drug therapies or
decompression. C1 (Japan V, overseas V; 7).
• Consider surgery in patients whose condition has not
been improved with medical treatment. B* (Japan V,
overseas V; 9).
Comments
Intestinal stenosis occurs with mucosal edema due to acute
inflammation or transmural fibrotic changes in the
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intestine. Patients with stenosis mainly due to inflam-
mation may improve with medical treatment such as
steroids [135]. In patients that do not show improvement
with anti-inflammatory treatments, suspect stenosis due
to fibrosis, and consider the possibility of endoscopic
dilation on the basis of the length of the stenosis, the
number of stenotic sites, and the presence of ulcers. It is
advisable to use endoscopic dilation when the inflam-
mation and ulcers have disappeared or become reduced
with enteral nutrition or other therapies. In a report
overseas, endoscopic dilation brought about favorable
results in 40 % of the subjects [136]. A report from Japan
showed the 5-year operation-free rate after endoscopic
dilation was 58 % [115]. Whether or not anti-TNF agents
are indicated for cases of CD with stenosis has not yet
been determined.
V-9. Hemorrhage
CQ10: What is the treatment for hemorrhage
from the CD lesions? [137–140]
• First apply conservative management such as support-
ive care and drug therapies. C1 (Japan V, overseas V;
9).
• Infliximab was reported to be effective in arresting
hemorrhage. C1 (Japan V, overseas V; 8).
• If conservative management is not successful in
arresting hemorrhage, surgery is indicated. B* (Japan
V, overseas V; 9).
Comments
Massive hemorrhage may occur in CD, although it is
rare. In such cases, first perform intensive conservative
management, and allow nothing by mouth to keep the
intestinal tract at rest. It was reported that steroids were
efficacious in such cases. Try endoscopic hemostasis
where it is applicable. With regard to angiography, it was
reported that the intraarterial injection of vasopressin and
arterial embolization were successful in arresting hem-
orrhage [137]. However, arterial embolization may cause
intestinal ischemia leading to intestinal necrosis. It was
reported that the administration of infliximab was
effective for treating the hemorrhagic type of CD [138].
Surgical treatment is necessary in cases where medical
treatment is unsuccessful. It was reported that the surgical
operation rate for hemostasis in patients with initial mas-
sive hemorrhaging was 20–90 %, and that the surgical
operation rate in those with recurrent hemorrhage under
medical treatment was 30–35 % [139, 140].
V-10. Abscesses
CQ11: What diagnosis and treatment are used
for abscesses due to CD? [141–144]
• Imaging examinations such as CT, US, and MRI are used
to diagnose abscesses. B (JapanV, overseas IVb; 9).
• Where possible, perform image-guided (e.g., CT-
guided) percutaneous drainage. B (Japan V, overseas
IV; 8).
• In patients with abscesses in the perianal region,
perform incision and drainage. B* (Japan V, overseas
V; 9).
• In patients in whom abscesses recur after percutaneous
drainage or in those with fistulas, surgical treatment is
likely to be necessary. B* (Japan V, overseas V; 8).
Comments
In CD, abscesses may be found to be complicated with
transmural lesions in the intestinal wall. A Japanese report has
indicated that the frequency of such abscesses is approxi-
mately 10 % [141]. CT, MRI, and ultrasonographic exami-
nation are useful in diagnosing abscesses [142]. For treatment,
percutaneous drainage should be performed where possible.
The drainage techniques include CT-guided percutaneous
drainage, US-guided percutaneous drainage, or surgical
drainage via a small incision. In patients having percutaneous
drainage, administer an antimicrobial drug with a broad
spectrum. Some overseas reports have indicated that percu-
taneous drainage avoided subsequent surgical operation in
50–69 % of the patients treated [143, 144]. Patients with
abscesses that cannot be controlled by percutaneous drainage
require surgical treatment.
V-11. Extra-intestinal complications
CQ12: What is the treatment for extra-intestinal
complications of CD? [145–147]
• In patients with active intestinal lesions, treat the
intestinal inflammation. C1 (Japan V, overseas V; 8).
• In patientss with pyoderma gangrenosum or uveitis,
administer steroids. C1 (Japan V, overseas V; 8).
• In patients with extra-intestinal complications, the useful-
ness of infliximab was reported. A (overseas II; 8).
Comments
Extra-intestinal complications in CD include those related
to the activity of the intestinal lesions (e.g., some types of
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peripheral arthritis, erythema nodosum, episcleritis, and
intraoral aphthous ulceration) and those unrelated to the
activity of the intestinal lesions (pyoderma gangrenosum,
uveitis, sacral arthritis, and ankylosing spondylitis). For
either category, it is necessary to intensively control the
inflammation of the intestinal lesions.
In patients with arthritis, a 5-ASA preparation such as
SASP is the first choice. Avoid NSAIDs because they may
exacerbate the intestinal lesions. Administer steroids for
serious complications such as pyoderma gangrenosum and
uveitis.
Some randomized and non-randomized controlled
studies, including those with non-CD patients, have indi-
cated that infliximab was effective for treating complica-
tions such as pyoderma gangrenosum, arthritis, uveitis, and
ankylosing spondylitis [145–147].
VI. Remission maintenance treatment
VI-1. General principles for preventing relapse
CQ1: Are there any lifestyle factors that require
attention to prevent relapse? [18, 70, 148, 149]
• If the patient smokes, advise them to refrain from
smoking. B (overseas III; 9).
• Advise the patient to avoid irregular lifestyle and eating
habits, and to refrain from excessive alcohol drinking.
C1 (overseas VI; 7).
• Advise the patient to adopt a lifestyle without excessive
mental stress, to have as little stress as possible. C1
(overseas IVb; 7).
• Advise the patient that in using an analgesic or an
antipyretic, wherever possible to avoid NSAIDs. C1
(overseas IVb; 7).
Comments
Although exacerbating factors common to all cases of
CD cannot be specified, it has been shown that smoking
contributes to the disease becoming refractory or
relapsing [148], and that the disease is attenuated after
smoking cessation [70]. Frequent or excessive alcohol
drinking may damage the intestinal tract, and therefore
drinking should be controlled. In view of the fact that
nutritional therapies are beneficial for CD, irregular
eating habits or unbalanced diets may precipitate
relapse.
It has also been shown that mental stress has some
relationship with CD relapse [149]. Patients with CD
should be advised to live without mental stress as much as
possible, and to adopt a lifestyle where stress does not
accumulate. NSAIDs are known to cause gastrointestinal
injuries, and also the relapse or exacerbation of CD.
Therefore, wherever possible, they should be avoided. If
analgesics or antipyretics need to be prescribed, acetami-
nophen would be an appropriate substitute [18].
CQ2: Are there any distinctive features of CD
that make the disease likely to relapse? [31, 150]
• CD patients with fistulas, perforation, or perianal
lesions, and those who have had resection of the
intestinal tract, are more susceptible to relapses. C1
(Japan V, overseas V; 7).
• Patients with CD who have required steroids for
induction of remission are more susceptible to relapses.
C1 (overseas IV; 7).
Comments
The pathophysiology and symptomatology of CD are
complex, and it is difficult to predict the variable progress
of each case. However, it has been shown that patients
with fistula formation or intestinal perforation are more
susceptible to relapses than those with the non-perforation
type [150]. Patients with CD with high disease activity
who have required steroids for the induction of remission
often have difficulty in withdrawing from the steroids and
require immunomodulators. It has been shown that
patients for whom steroids or immunomodulators are
required are more susceptible to relapses than other
patients [31].
VI-2. Drug treatment
CQ3: Which drugs are effective for maintaining
remission of CD? [76, 79, 128, 151–153]
• AZA is effective in maintaining remission. A (overseas
I; 9).
• In patients in whom remission was induced by anti-
TNF agents, the scheduled administration of anti-TNF
agents is effective in maintaining remission. A (over-
seas II; 8).
• 5-ASA preparations are effective in maintaining remis-
sion postoperatively. B (overseas II; 7).
Comments
Steroids are effective for inducing remission, but ineffec-
tive for maintaining remission. It has been shown that AZA
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and 6-MP have steroid-sparing effects in steroid tapering
and complete withdrawal, as well as having a long-term
effect in maintaining remission. The standard dose of AZA
is 1.0–2.5 mg/kg daily, and that of 6-MP is half of that of
AZA. A high dose of these drugs exhibits a more potent
effect than a low dose [79, 151]. However, both AZA and
6-MP may produce serious side effects, and the doses that
may produce the required effects and the adverse reactions
differ individually. The recommended doses for these
agents have been determined for patients in Western
countries, and it is possible that lower doses in Japanese
patients would produce the required effects and/or fewer
adverse effects.
It has been shown that infliximab exhibits a remis-
sion induction effect even in refractory or severe cases,
and that administration of infliximab every 8 weeks to
patients in whom remission was induced by the agent
had a significant effect in preventing relapses for at
least 1 year [128, 152]. 5-ASA preparations have only
a limited remission maintenance effect [76], but they
are effective in controlling postoperative relapses
[153].
CQ4: How long should the treatment for remission be
continued? [128, 152, 154]
• If effective, it is advisable to continue the administra-
tion of AZA or 6-MP* for 3–4 years. C1 (overseas VI;
8) *Not covered by Japanese public health insurance
for treatment of CD.
• Scheduled administration of infliximab is effective for
at least 1 year. A (overseas II; 8).
Comments
AZA and 6-MP, thiopurine derivatives, are known to
have efficacy for long-term remission, and a meta-anal-
ysis showed that they were effective in maintaining
remission for at least 1 year. Furthermore, it has been
reported that the continued administration of these
agents for more than 2 years is effective, and therefore it
is advisable that they continue to be administered for
3–4 years as long as remission is maintained without the
emergence of adverse effects [154]. In a study to eval-
uate the effect of the scheduled administration of inf-
liximab at 8-week intervals for 1 year in patients in
whom remission was induced by infliximab, the remis-
sion maintenance effect was significantly higher in the
group receiving infliximab regularly at intervals of
8 weeks compared with placebo [128, 152].
VI-3. Nutritional therapy
CQ5: Is home enteral nutrition effective in maintaining
remission? [103, 155, 156]
• Replacing half of the daily caloric intake by enteral
nutrients is effective in maintaining remission. A (Japan
II, overseas II; 8).
Comments
Enteral nutrition as a long-term therapy for remission
maintenance has an excellent safety profile, but often lacks
acceptability and convenience. It is thus difficult for
patients to receive total enteral feeding at home for a long
period of time. Partial enteral feeding is more acceptable
and more convenient for the patient, and the patient can
enjoy eating as well. It was shown that replacing 30–50 %
of the normal daily caloric intake by enteral nutrients had a
significantly higher remission maintenance rate than a
normal daily diet only [103, 155, 156].
CQ6: How long should nutritional therapy be
continued? [103, 155, 156]
• Replacing half of the daily caloric intake by enteral
nutrients is effective in maintaining remission for at
least one year. A (Japan II, overseas II; 8).
Comments
It was shown that replacing 30–50 % of the daily caloric
intake by enteral nutrients had a significantly higher rate of
remission maintenance at 1 year than a normal daily diet
only [103, 155, 156]; therefore, it is recommended to
continue enteral nutrition for 1 year in patients in whom
remission was induced by nutritional therapy. Although
there is no evidence to favor enteral nutrition beyond
1 year, it may be advisable to continue this treatment for as
long as possible, if no problems of acceptability or con-
venience emerge.
CQ7: When is home parenteral nutrition (HPN)
necessary, and how is it performed? [157]
• In patients with short-bowel syndrome for whom suf-
ficient nutritional care by enteral feeding is not possi-
ble, supply nutrition by infusion through a central
venous line. C1 (Japan VI, overseas VI; 8).
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Comments
In CD patients with small-intestinal lesions where the
remaining small intestine is short as a result of the resection
of a large area or frequent resections, the bowel cannot
digest and assimilate a sufficient amount of nutrition (i.e.,
if the remaining small intestine is 1 m or less, malab-
sorption is inevitable; even if the remaining small intestine
is a little longer, malabsorption is likely to occur).
Accordingly, to provide the patient with the required
nutritional support, a catheter is placed in the central vein,
and a home-based arrangement is made whereby the
patient or the patient’s family can manage nutrition drips
[157].
VII. Surgical treatment
VII-1. Indication for surgery
CQ1: How often is surgical treatment required for CD?
[158, 159]
• In Japan, the cumulative rate of surgical intervention
for CD at 5 and 10 years after the onset is 30.3 and
70.8 %, respectively. The rates vary greatly from area
to area in Europe and North America. C1 (Japan V,
overseas V; 7).
Comments
In Japan, the cumulative rates of surgical treatment for CD
at 5 and 10 years after the onset are 30.3 and 70.8 %,
respectively (N = 361). Regarding the rate according to
the disease location, there were no significant differences
among the ileal, ileocolonic, and colonic types at 5 and
10 years after the disease onset [158]. In Europe and North
America, the rate of surgical treatment for CD varies from
area to area [159].
CQ2: What are the absolute indications and the relative
indications for surgery? [141, 160, 161]
• Surgery is absolutely indicated in patients with perfo-
ration, massive hemorrhage, development of cancer,
bowel obstruction not alleviated by medical therapies,
and abscesses. B* (Japan V, overseas V; 9).
• Surgery is relatively indicated in patients with refrac-
tory stenosis or internal and external fistulas, and in
those refractory to medical treatment, or with refractory
extra-intestinal complications (e.g., growth retardation,
pyoderma gangrenosum), and refractory perianal
lesions. C1 (Japan V, overseas: V; 8).
Comments
Surgical indications in CD, in percentages according to the
underlying lesions or clinical situations, are as follows:
bowel obstruction and stenosis: 54 %; fistulas: 28 %;
abscesses: 7 %; perforations: 4.5 %; cases refractory to
medical therapies: 3.5 %; massive hemorrhage: 2 %; and
colorectal cancer: 1 %. Toxic megacolon was also referred
to as a surgical indication. Other surgical indications are:
symptomatic fibrotic stenosis; enterocutaneous fistulas with
excessive leaks of intestinal juices or with stenosis;
symptoms due to bypass formation (e.g., duodenal/trans-
verse colonic fistulas); intestinal fistulas involving a broad
area of intact bowel; enterovesical fistulas refractory to
medical therapies and with repeated urinary tract infection;
intra-abdominal abscesses not responsive to medical ther-
apies; and retroperitoneal abscesses [141]. The relative
risks of colorectal cancer and small-intestinal cancer are
significantly high in patients with CD [161]. In Japan,
colorectal cancer in CD patients is more common in the
form of rectal and anal fistula cancer, and small-intestinal
cancer is more common in the ileum. With regard to gas-
tric/duodenal lesions as complications of CD, surgical
indications are fistulas starting at the colon or ileo-colonic
anastomosis to the stomach, long duodenal stenosis, and
duodenal fistulas that often occur arising from the adjacent
lesions [160].
VII-2. Refractory to medical treatment
CQ3: What is the main principle guiding surgery
on the intestine? [162, 163]
• As CD involves the entire intestinal tract and often
recurs, the intestinal tract should be preserved as much
as possible. A (overseas II; 9).
• Only the small portion of the intestinal tract causing
stenosis or fistulas should be resected. Strictureplasty
should be performed in patients with short fibrotic
stenosis in the small intestine or in those with a short
length of small intestine remaining. C1 (Japan V,
overseas V; 9).
Comments
The postoperative recurrence of CD after resection of the
intestine is unrelated to the distance between the lesion and
the resected end [162], or to the histological residue of the
lesion at the resected ends [163]. Therefore, in principle, a
short segment should be resected. In patients with an
intestinal fistula induced by another intestinal lesion, the
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intestinal area of the principal lesion is resected, and the
fistulized area is wedge-resected. Strictureplasty is per-
formed to preserve the small intestine. Bypass operations
result in a high incidence of malignant tumors in the
diverted residual lesion, and a high rate of reoperation. In
principle, therefore, only gastrojejunostomy for duodenal
stenosis is performed in patients with CD.
VII-3. Stenosis
CQ4: What kind of surgery is used to treat stenosis?
[164–166]
• Only the area of the lesion causing the stenosis should
be resected. Strictureplasty should be performed for a
short segment of fibrotic stenosis in the small intestine
or in patients with a short length of small intestine
remaining. B (Japan V, overseas IVb; 8).
Comments
It is a general opinion that there is little difference in
postoperative recurrence rates between strictureplasty and
intestinal resection [164]. In patients with a stenosis in a
short segment, the Heineke-Mikulicz technique is applied;
in those with stenosis over a long segment, the Finney
technique or the Jaboulay technique is applied; and in those
with stenoses close to one another, a more complex anas-
tomosis technique is applied [165, 166]. Furthermore, it is
important to conduct a biopsy examination at the stenosis
to exclude cancer. The effectiveness of strictureplasty on
colonic stenosis is yet to be confirmed.
VII-4. Perianal lesions
CQ5: What kind of surgery is used to treat perianal
lesions? [38, 167, 168]
• Perianal lesions in CD are classified as primary lesions
(cavitating ulcerative lesions due to CD), secondary
refractory lesions (secondary lesions originating from a
primary lesion via infection and other causes), and
incidental lesions (lesions not associated with CD). C1
(overseas VI; 7).
• For incidental lesions, use ordinary treatments generally
appropriate for such lesions. C1 (Japan VI, overseas VI; 7).
• Among the secondary refractory lesions, a Seton
technique is used for low intersphincteric fistulas and
ischiorectal fistulas. Consider creating a stoma in cases
not responsive to the Seton technique or in those with
fibrotic stenosis. C1 (Japan VI, overseas VI; 8).
Comments
In the diagnosis of perianal lesions in CD, determine
whether the lesion is a secondary refractory lesion or an
incidental lesion, on the basis of the presence or absence
of a primary lesion characteristic of CD in the anal canal
and the fistula (e.g., whether or not there are multiple
fistulas, the location, and so on [167]; refer to the Atlas of
findings by visual observation of lesions in the anus of
Crohn’s disease [38]). The refractory fistulas most fre-
quent in CD are secondary lesions. Cancer complications
are found more commonly in the rectum and anal canal
(including fistulas) in patients with long-term progression
of CD [168]. For the treatment of refractory fistulas, use
medical treatment (nutritional therapy, and drug therapies
such as metronidazole or steroids) for the primary lesion,
and try to induce remission if there are active rectal
lesions. Subsequently, if no improvement is observed, use
surgical treatment on the fistulas. For local treatment, as a
general rule, use a Seton drainage technique to establish a
drain to eventually discharge pus in the fistula. Consider
creating a stoma in patients with fistulas or rectal stenosis
that cannot be controlled with the Seton technique. For
lesions of rectal stenosis with fistulas, consider rectal
amputation.
CQ6: Is it possible to close a stoma later? [169, 170]
• In principle, a stoma that has been created because of
rectal/anal lesions in CD is not closed because the
lesions tend to recur frequently if it is closed. C1 (Japan
V, overseas V; 7).
Comments
In a report of stoma closure surgery in 16 patients with
symptomatic improvement out of 42 patients who under-
went colostomies for refractory rectoanal lesions as com-
plications of CD, 75 % required re-creation of the stoma
[169]. It has been reported overseas that the cumulative
rate of stoma closure in 5 years was 40 % [170].
VII-5. Postoperative management
CQ7: What is the relapse rate after surgical treatment?
[171–173]
• Relapse after intestinal resection is frequently discov-
ered early by means of endoscopic exploration. The
cumulative reoperation rates were 16–43 % at 5 years
and 26–65 % at 10 years. C1 (Japan V, overseas V; 8).
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Comments
Postoperative relapse has been defined separately on the
basis of endoscopic or contrast imaging findings, or on
the basis of reoperation, and so the reported rates of
relapse vary. The rate of relapse found by means of
endoscopic exploration (in an ileocolonic anastomosis)
seemed to be 72 % within 1 year after the operation
[171], indicating that the lesions tend to recur early. It
was reported that the cumulative reoperation rates were
16–43 % at 5 years and 26–65 % at 10 years [172,
173].
CQ8: What are the risk factors for a relapse? [164, 172,
174–176]
• Gender and the presence of granuloma are not signifi-
cant risk factors. In patients who have had operations
on the colonic lesions of CD, reoperation is not fre-
quent. C1 (overseas V; 7).
• The length of the uninvolved area in the resection
margins is not a significant risk factor. C1 (overseas V;
7).
• No consensus has been reached on the disease duration
before the initial operation, the presence or absence of
histological inflammation at the resection margins, or
the types of anastomosis (end-to-end, end-to-side, or
functional end-to-end) as risk factors. C1 (Japan VI,
overseas VI; 8).
• In patients where fistulization is the surgical indication,
the reoperation rate may be higher in comparison with
that in patients with a non-fistulizing type. B (overseas
IVb; 8).
• It was reported that there was little difference in terms
of recurrence rates between strictureplasty and intesti-
nal resection. C1 (overseas IVb: 7).
Comments
Risk factors for recurrence have not been determined.
Gender and the presence or absence of granuloma are not
significant risk factors. In patients who have had opera-
tions on the colonic lesions of CD, reoperation is not
frequent [172]. The length of the intact area in the
resection margins is not a significant risk factor [174].
There are contradictory reports on the disease duration
before the initial operation and the presence or absence of
histological inflammation at the resection margins as risk
factors. There is no consensus on the type of anastomosis
(end-to-end, end-to-side, or functional end-to-end) as
a risk factor. Reports about the types of surgical indica-
tion (perforating versus non-perforating) are also
contradictory [175]; however, a meta-analysis has indi-
cated that the perforating type shows a higher reoperation
rate [176]. It was reported that there was little difference
in terms of recurrence rates between strictureplasty and
intestinal resection [164].
CQ9: How can postoperative relapse be prevented?
[105, 177–179]
• There are no established measures to prevent relapse.
C1 (Japan VI, overseas VI; 7).
• 5-ASA, 6-MP*, and metronidazole* may be effective
in preventing a postoperative relapse. B (overseas II; 7).
*Not covered by Japanese public health insurance for
treatment of CD.
• The effect of postoperative nutritional therapies to
prevent relapse is unclear. C1 (Japan V; 7).
Comments
The effects of surgical procedures, drug therapies, and
nutritional therapies on relapse have been studied. With
regard to surgical procedures, there are different views
on the comparison between conventional end-to-end
anastomosis and functional end-to-end anastomosis (in
which the anastomotic site opening is wider in order to
improve the retention of intestinal contents, which is
considered to be a cause of relapse).
5-ASA (3,000 mg daily) exhibited significantly better
results, in terms of clinical symptoms and relapse rate
defined by endoscopy and contrast radiography, in com-
parison with a placebo group [177]. In patients who
underwent ileal resection, metronidazole (20 mg/kg) was
superior to placebo in terms of endoscopic relapse at
3 months after the operation, and in regard to the relapse
rate at 1 year, but the relapse rates in the two groups were
similar at 2 and 3 years after the operation [178]. In
subjects with ileal resection, the 6-MP group (50 mg
daily) exhibited significantly lower recurrence rates,
according to the clinical symptoms, and endoscopic and
contrast radiographic findings, at 2 years after the oper-
ation in comparison with the 5-ASA group and the pla-
cebo group [179]. Corticosteroids do not have efficacy to
prevent postoperative relapse. Studies of the effects of
anti-TNF agents to prevent postoperative recurrence have
not been sufficient to reach definitive conclusions on such
effects.
The long-term application of nutritional therapy
(approximately 1,000 kcal daily) is difficult in many cases.
A report has indicated that nutritional therapies were
effective in preventing postoperative relapse [105], but the
issue remains controversial.
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VIII. Follow-up
VIII-1 Routine follow-up schedule
CQ1: How are CD patients followed, and what kind
of examinations are required? [180, 181]
• Advise patients to have regular examinations, and
observe changes in the clinical symptoms (abdominal
pain, diarrhea, fever, and others). C1 (Japan VI, over-
seas VI; 8).
• CRP, ESR, complete blood counts, and serum albumin
level correlate with the disease activity. C1 (Japan VI,
overseas VI; 8).
• If changes in disease activity are noted, employ
imaging examinations to observe the lesions. C1 (Japan
VI, overseas VI; 8).
Comments
Blood tests are convenient and are the first-line exami-
nation to observe progress. CRP and ESR in particular
were reported to correlate with the disease activity.
Anemia and hypoalbuminemia can be indices of broadly
spread lesions or highly active lesions, and hypoprotein-
emia is often found, particularly in patients with small-
intestinal lesions. When changes in the disease activity
are noted (clinical relapse, bowel obstruction, abscess,
fistula), it is advisable to conduct examinations according
to the previous pathophysiological conditions (the disease
extent and possibility of complications) [181]. To deter-
mine the activity of intra-abdominal inflammation and the
extent of active lesions, abdominal and pelvic CT and
MRI are useful.
To evaluate diffuse small-intestinal lesions, radiographic
examinations are often more advantageous than endoscopy
or capsule endoscopy [180].
VIII-2. Morphological examination
CQ2: When is endoscopy or contrast radiography
necessary? [150]
• When changes in disease activity or pathophysiological
conditions are noted (clinical relapse, or complications
such as bowel obstruction, abscesses, and fistulas), it is
advisable to perform diagnostic imaging such as
endoscopy and contrast radiography to assess the dis-
ease. C1 (Japan VI, overseas VI; 8).
Comments
A study of the long-term prognosis of CD indicates that
even in patients with the non-stricture and non-penetrating
type without complications in their initial stage, approxi-
mately 30 % progressed to having stenosis or fistulas
[150]. It is not unlikely that the lesions progress even in
patients with stable disease, and therefore, annual endo-
scopic examinations or contrast radiographic examinations,
as far as possible, would be helpful in assessing the path-
ological conditions.
VIII-3. Cancer surveillance
CQ3: Is the risk of cancer increased in CD, and can it be
prevented? [25, 26, 182–185]
• Both colonic and ileocolonic CD have a higher risk of
colorectal and/or anal cancer than that in the general
population. B (Japan IVb, overseas IVa: 8).
• The incidence of small-intestinal cancer in patients with
CD is low, but the relative risk is high in such patients.
C1 (overseas IVa; 7).
• There is no evidence that the administration of
immunomodulators increases the incidence of malig-
nant tumors. C1 (overseas IVa; 7).
• Preventive measures against the occurrence of cancer in
patients with CD are not known, but control of the
intestinal inflammation is considered to be important.
C1 (Japan VI, overseas VI: 7).
• There are no data to clearly show that 5-ASA reduces
the risk of colorectal cancer in CD. C1 (overseas VI; 7).
Comments
A meta-analysis of analytical epidemiological studies
indicated that the relative risk of colorectal cancer was 2.5
in all types of CD, and significantly higher, at 4.5, in
colonic-type CD; the relative risk of small-intestinal cancer
was extremely high, at 33.2, in all types of CD [182].
Another epidemiological study indicated similar results
[183]. Although Japanese data on these risks are sparse,
some studies of the colorectal/anal canal cancer and small-
intestinal cancer complications of CD indicate that most
cases are found as advanced cancer, but the incidence is not
different from that in Europe and the United States [25,
26].
A meta-analysis of analytical epidemiological studies
has reported that there was no significant difference in the
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occurrence of malignant tumors between groups with and
without administration of immunomodulators [184]. The
TREAT study presents no evidence that a group in which
infliximab was administered had an increased occurrence
of malignant tumors. However, it has been reported that 13
cases of hepato-splenic T-cell lymphoma (HSTCL)
occurred in a group in which infliximab and AZA were
administered in combination [185]. No causal relationship
has been established between such drugs and cancer.
It is assumed that controlling the intestinal inflammation
is effective in preventing cancer in CD, as it is in UC. It has
been suggested that 5-ASA has a suppressive effect on
inflammatory carcinogenesis in UC, but there are no such
data for CD.
CQ4: How is cancer surveillance conducted? [25, 186]
• There is no effective cancer surveillance program at
present. C1 (Japan VI, overseas VI; 8).
Comments
In patients with long-term disease, it is advisable to con-
duct endoscopic and contrast imaging examinations, as
appropriate, as well as to check the condition of anal fis-
tulas. However, there are patients in whom it is difficult to
conduct examinations to evaluate the small intestine in
detail in the presence of stenosis. Appropriate determina-
tion of a high-risk group and an effective screening pro-
gram are awaited.
In observing the progression of CD, it should be noted
that the risks of small-intestinal cancer and colorectal
cancer are high, particularly in the long-term progression of
the disease, and that anal fistula cancer with diagnostic
difficulty does occur, although the frequency is unknown. It
was reported that surveillance endoscopy, like that for UC,
was helpful in finding colorectal cancer [25, 186]. How-
ever, several issues remain unsolved, such as how to con-
duct surveillance in patients with stenotic lesions, and
therefore surveillance colonoscopy has not yet become a
general practice.
CQ5: Does CD increase the risk of extra-intestinal
malignant tumors, and how is surveillance for such
tumors conducted? [185, 187, 188]
• A combination of infliximab and immunomodulators
may increase the risk of malignant lymphoma. C1
(overseas V; 7).
• There is no established program for the surveillance of
malignant tumors in regions other than the intestinal
tract. C1 (Japan VI, overseas VI; 8).
Comments
In patients with rheumatoid arthritis (RA), a study reported
that it was unlikely that a combination of an anti-TNF
agent with MTX raised the risk of lymphoma; on the other
hand, another study indicated that the long-term use of a
combination of an anti-TNF agent with an immunomodu-
lator (AZA or 6-MP) did not raise the risk of solid cancer,
but did raise the risk of malignant lymphoma [187, 188]. In
particular, it has been reported that HSTCL, which is
extremely rare, occurred in CD groups receiving combi-
nation therapy [185]. The pathophysiology of CD is dif-
ferent from that of RA, and the concomitant therapeutic
drugs used and the clinical courses are different; because of
these problems, no conclusion has been reached in regard
to the risk of lymphoma with combination therapy in CD.
IX. Pregnancy and delivery
IX-1. Pregnancy
CQ1: Is CD exacerbated during pregnancy or in relation
to the menstrual cycle? [189]
• There is no evidence that CD is exacerbated by either
pregnancy or the menstrual cycle. C1 (Japan VI,
overseas V; 8).
Comments
Not many studies have been carried out to evaluate the effect
of pregnancy on CD. A study involving a small number of
pregnant CD patients (12 patients; 18 pregnancies) indicated
that pregnancy was unlikely to be a factor exacerbating CD
[189]. Adherence with taking medications, however, may get
worse due to the fear of taking drugs during pregnancy. It is
necessary to explain the need for the medications to pregnant
patients, so that the patients have a good understanding of the
benefits and harms of the drugs.
There are no reports on the relationship between the
menstrual cycle and exacerbation of CD, and clinical
experience indicates that the cycle has no significant effect
on CD. However, there is a possibility that variations in
estrogen secretion have some effect on the immune system,
and this requires further study.
CQ2: Do CD patients have different fertility rates
from those of healthy individuals? [190–193]
• Many reports indicate that patients with CD have
reduced fertility; on the other hand, some other reports
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show no significant differences from fertility rates in
the general population. B (overseas IVb; 8).
Comments
Many reports have indicated that both male and female
patients with CD have fewer children than the general
population [190–192]. It was reported that the frequency of
sexual intercourse was lower in female patients with CD
because they were afraid of abdominal pain or fecal leaks
[193]. There is a possibility that men who are administered
SASP have reduced fertility [191].
CQ3: Is modification of the treatment necessary
for pregnant patients with CD? [194–202]
• Devise treatment strategies according to the disease
activity, considering the benefits and harms of the
drugs. C1 (Japan VI, overseas VI; 8).
• Dominant overseas opinions are to treat pregnant CD
patients similarly to non-pregnant patients. C1 (over-
seas VI; 8).
• In Japan, 5-ASA preparations, small to medium doses
of steroids, and nutritional therapies are considered to
be relatively safe in pregnant patients, but it is desirable
to avoid immunomodulators. C1 (Japan VI; 7).
• When using nutritional therapies in pregnant patients,
avoid excessive administration of vitamin A. C1 (Japan
VI, overseas VI; 8).
• There is a possibility that the administration of AZA or
6-MP is associated with pre-term delivery, low birth
weight, and fetal malformation. C1 (overseas IVa; 7).
• Infliximab has been reported to be relatively safe, but
the relevant data are not sufficient. B (overseas IVb; 8).
Comments
Experts in Japan and overseas have different opinions
concerning drug therapies for pregnant patients. Japanese
specialists are cautious about using drugs because of the
possibility of adverse effects, while overseas specialists
assign priority to the benefits of the drugs unless they are
confirmed to be harmful.
Several reports have indicated that the relative risks of
pre-term delivery, low birth weight, and fetal deformation
were high in groups administered AZA and 6-MP [194];
however, this does not exclude the possibility that other
factors, such as high CD disease activity, were involved in
these patients. Moreover, CD itself could pose such risks
[195–197]. Recently, the number of reports overseas that
have emphasized the safety of AZA has increased [198,
199].
Some reports have emphasized that the administration of
infliximab or adalimumab in pregnancy was not associated
with abnormal births; however, these reports were based on
studies with a small number of subjects, and thus the safety
of these drugs in pregnant patients could not be guaranteed
[200, 201]. It has been reported that 5-ASA preparations
are comparatively safe in pregnancy [202].
CQ4: What is the treatment for CD exacerbation
during pregnancy? [198, 199, 201–203]
• Devise treatment strategies according to the disease
condition, considering the benefits and harms of the
drugs. C1 (Japan VI, overseas VI; 8).
• First increase the dose of a 5-ASA preparation, and
reinforce nutritional therapy. C1 (Japan VI; 8).
• If the result of the above is not sufficient, use steroids,
an immunomodulator, and/or an anti-TNF agent, con-
sidering their benefits and harms. C1 (Japan VI; 7).
Comments
According to the FDA’s pharmaceutical categories for
safety in pregnancy, 5-ASA preparations and infliximab are
in category B, oral prednisolone is in category C, and AZA
and 6-MP are in category D [203]. A study of 131 pregnant
women (with RA or CD) who were treated with infliximab
indicated that 15 % experienced birth abnormalities, and
therapeutic abortion was induced in 19 %; these findings
correspond to the expected values for the general American
population [201].
Despite the information mentioned above, many
overseas textbooks recommend that the risk of such
drugs be compared with the risk of CD relapse if their
administration is terminated. Specifically, many overseas
opinions appear to consider the risk of relapse or exac-
erbation of CD to pose a greater risk to pregnancy. As a
result, many consider that AZA and 6-MP are relatively
safe, and that they should continue to be administered
when the patient becomes pregnant [198, 199]. On the
other hand, MTX is contraindicated for pregnant women
[202].
IX-2. Lactation
CQ5. What is the treatment for CD during a period
of lactation? [202, 204, 205]
• Only a few drugs have been proven to be safe during
breastfeeding, but nutritional therapy is considered
safe. C1 (Japan VI, overseas VI; 8).
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• Devise treatment strategies according to the disease
activity, considering the benefits and harms. C1 (Japan
VI, overseas VI; 8).
Comments
Data are sparse on the transfer of therapeutic drugs for CD into
breast milk and potential exposure to breastfed infants. It has
been found that 5-ASA is transferred into breast milk [204,
205]. However, there are many opinions that suggest it is safe
in normal use. It is advisable to avoid administering a high
dose of 5-ASA to lactating women. There are no relevant data
with respect to AZA and 6-MP; on the other hand, MTX and
cyclosporine are contraindicated in lactating women [202].
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